<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML><HEAD><TITLE>MCB -- Sadot et al. 21 (20): 6768</TITLE>
<META content="text/html; charset=utf-8" http-equiv=Content-Type>
<SCRIPT language=JavaScript>
	<!--
	function startTarget(windowname,wid,hei) {
	
	var dotpos = windowname.indexOf(".");
	if (dotpos > -1)
	{
	var tempwn = windowname.substring(0,dotpos) +
		windowname.substring(dotpos + 1, windowname.length);
	windowname = tempwn;
	}
	var sizestring = 'width=' + wid + ',height=' + hei;
	window.open('',windowname,'scrollbars,resizable,' + sizestring + '\'');
	}
	// -->
	</SCRIPT>
<!-- has inhead tag -->
<SCRIPT language=JavaScript>
	<!--
	if ( top != self )
	{
		top.location.href = unescape(window.location.pathname);
	}
	//-->
	</SCRIPT>

<META content=nofollow name=robots>
<META content="MSHTML 5.00.3513.900" name=GENERATOR></HEAD>
<BODY bgColor=#ffffff><A name=top><!-- null --></A><NOBR><A href="/" 
style="TEXT-DECORATION: none" target=_top><IMG alt=MCB border=0 height=44 
src="/icons/banner/title.gif" width=220></A> <A 
href="/cgi/adclick?journal=mcb&amp;ad=EC%20%32%30%30%33&amp;url=http://ec.asm.org/&amp;side=only" 
target=_top><IMG alt="EC Online 2003 " border=2 height=40 
src="/ads/gifs/1050673403.gif" width=220></A> </NOBR><BR><NOBR><A href="/" 
target=_top><IMG alt=Home border=0 height=15 src="/icons/banner/homeACT.gif" 
width=40></A> <A href="/help/" target=_top><IMG alt=Help border=0 height=15 
src="/icons/banner/helpACT.gif" width=36></A> <A href="/cgi/feedback" 
target=_top><IMG alt=[Feedback] border=0 height=15 
src="/icons/banner/feedbackACT.gif" width=56></A> <A href="/subscriptions/" 
target=_top><IMG alt="[For Subscribers]" border=0 height=15 
src="/icons/banner/subscriberACT.gif" width=95></A> <A 
href="/contents-by-date.0.shtml" target=_top><IMG alt=[Archive] border=0 
height=15 src="/icons/banner/archiveACT.gif" width=57></A> <A href="/search.dtl" 
target=_top><IMG alt=[Search] border=0 height=15 
src="/icons/banner/searchACT.gif" width=44></A> <A 
href="/content/vol21/issue20/index.shtml" target=_top><IMG alt=[Contents] 
border=0 height=15 src="/icons/banner/tocACT.gif" width=100></A> </NOBR><!-- NOT GUEST -->
<HR align=left color=#000000 noShade SIZE=1 width=450>
<!-- beginning of outer tables -->
<TABLE align=right border=1 cellPadding=4 NOWRAP VSPACE="4" HSPACE="4">
  <TBODY>
  <TR>
    <TD align=left noWrap><!-- beginning of inner table -->
      <TABLE border=0 cellPadding=0 cellSpacing=1 NOWRAP>
        <TBODY>
        <TR>
          <TD><IMG align=baseline alt="" border=0 height=11 
            src="/icons/toc/rarrowsm.gif" width=9><FONT size=-1> <A 
            href="/cgi/content/abstract/21/20/6768">Abstract of this Article</A> 
            (<IMG src="/icons/shared/toc/free.gif">) </FONT></TD></TR>
        <TR>
          <TD><IMG align=baseline alt="" border=0 height=11 
            src="/icons/toc/rarrowsm.gif" width=9><FONT size=-1> <STRONG><A 
            href="/cgi/reprint/21/20/6768">Reprint (PDF) Version of this 
            Article</A> </FONT></STRONG></TD></TR>
        <TR>
          <TD><IMG align=baseline alt="" border=0 height=11 
            src="/icons/toc/rarrowsm.gif" width=9><FONT size=-1> Similar 
            articles found in:<BR><IMG align=baseline alt="" border=0 height=9 
            src="/icons/spacer.gif" width=9><IMG align=baseline alt="" border=0 
            height=9 src="/icons/spacer.gif" width=9><A 
            href="/cgi/search?qbe=mcb;21/20/6768&amp;journalcode=mcb&amp;minscore=4000"><FONT 
            size=-1>MCB Online</FONT></A> <BR><IMG align=baseline alt="" 
            border=0 height=9 src="/icons/spacer.gif" width=9><IMG 
            align=baseline alt="" border=0 height=9 src="/icons/spacer.gif" 
            width=9><A 
            href="/cgi/external_ref?access_num=11564862&amp;link_type=MED_NBRS"><FONT 
            size=-1>PubMed</FONT></A> </FONT></TD></TR>
        <TR>
          <TD><IMG align=baseline alt="" border=0 height=11 
            src="/icons/toc/rarrowsm.gif" width=9><FONT size=-1> <A 
            href="/cgi/external_ref?access_num=11564862&amp;link_type=PUBMED">PubMed 
            Citation</A> </FONT></TD></TR>
        <TR>
          <TD><IMG align=baseline alt="" border=0 height=11 
            src="/icons/toc/rarrowsm.gif" width=9><FONT size=-1> This Article 
            has been cited by: </FONT></TD></TR>
        <TR>
          <TD><FONT size=-1><IMG align=baseline alt="" border=0 height=9 
            src="/icons/spacer.gif" width=9><IMG align=baseline alt="" border=0 
            height=9 src="/icons/spacer.gif" width=9><A 
            href="#otherarticles">other online articles</A> </FONT></TD></TR>
        <TR>
          <TD><IMG align=baseline alt="" border=0 height=11 
            src="/icons/toc/rarrowsm.gif" width=9><FONT size=-1> Search Medline 
            for articles by:<BR><IMG align=baseline alt="" border=0 height=9 
            src="/icons/spacer.gif" width=9><IMG align=baseline alt="" border=0 
            height=9 src="/icons/spacer.gif" width=9> <A 
            href="/cgi/external_ref?access_num=Sadot+E&amp;link_type=AUTHORSEARCH">Sadot, 
            E.</A> || <A 
            href="/cgi/external_ref?access_num=Ben-Ze%27ev+A&amp;link_type=AUTHORSEARCH">Ben-Ze'ev, 
            A.</A> </FONT></TD></TR>
        <TR>
          <TD><IMG align=baseline alt="" border=0 height=11 
            src="/icons/toc/rarrowsm.gif" width=9><FONT size=-1> Alert me when: 
            <BR><IMG align=baseline alt="" border=0 height=9 
            src="/icons/spacer.gif" width=9><IMG align=baseline alt="" border=0 
            height=9 src="/icons/spacer.gif" width=9><A 
            href="/cgi/alerts/ctalert?alertType=citedby&amp;addAlert=cited_by&amp;saveAlert=no&amp;cited_by_criteria_resid=mcb;21/20/6768&amp;return_type=article&amp;return_url=%2Fcgi%2Fcontent%2Ffull%2F21%2F20%2F6768"><FONT 
            size=-1>new articles cite this article</FONT></A><BR></FONT></TD></TR>
        <TR>
          <TD><IMG align=baseline alt="" border=0 height=11 
            src="/icons/toc/rarrowsm.gif" width=9><FONT size=-1> <A 
            href="/cgi/citmgr?gca=mcb;21/20/6768">Download to Citation 
            Manager</A> </FONT></TD></TR></TBODY></TABLE></TD></TR><!-- end of inner content box -->
  <TR>
    <TD align=left noWrap><FONT size=-1><IMG align=baseline alt="" border=0 
      height=11 src="/icons/toc/rarrowsm.gif" width=9><A 
      href="http://www.asmpress.org/">Books from ASM 
      Press</A><BR><STRONG></FONT></STRONG></TD></TR><!-- 1xxx --><!-- 2xxx --></TBODY></TABLE><!-- end of outer content box --><VARDEF 
id=TEXT><!-- /COPYRIGHT --><!--

   Pages created by the Electronic Press Engine from

		Atypon Systems, Inc.

   Visit http://www.atypon.com/

-->
<P><FONT size=-1>Molecular and Cellular Biology, October 2001, p. 6768-6781, 
Vol. 21, No. 20<BR>0270-7306/01/$04.00+0 &nbsp;&nbsp;DOI: 
10.1128/MCB.21.20.6768-6781.2001<BR><A href="/misc/terms.shtml">Copyright Â© 
2001</A>, <A href="http://www.asmusa.org">American Society for Microbiology</A>. 
All rights reserved.</FONT> 
<H2>Down-Regulation of <IMG align=bottom alt="beta " 
src="/math/12pt/Large/beta.gif">-Catenin by Activated p53 
</H2><STRONG><NOWRAP>Einat Sadot,<WBR> Benjamin Geiger,<WBR> Moshe Oren, 
and<WBR> Avri Ben-Ze'ev<A href="#FN150">*</A> </NOWRAP></STRONG>
<P>Department of Molecular Cell Biology, The Weizmann Institute of Science, 
Rehovot 76100,&nbsp;Israel 
<P>
<P>Received 6 February 2001/Returned for modification 5 April 2001/Accepted 9 
July 2001 </P><A name=abs><!-- comment for mosaic --></A><BR clear=all><A 
name=Abstract><!-- null --></A>
<TABLE bgColor=#e1e1e1 cellPadding=0 cellSpacing=0 width="100%">
  <TBODY>
  <TR>
    <TD align=left bgColor=#ffffff vAlign=center width="5%">&nbsp;<IMG alt="" 
      height=21 hspace=5 src="/icons/toc/rarrow.gif" width=10></TD>
    <TH align=left vAlign=center width="95%"><FONT 
      size=+2>&nbsp;&nbsp;ABSTRACT</FONT></TH></TR></TBODY></TABLE>
<TABLE align=right border=1 cellPadding=5 NOWRAP><R>
  <TBODY>
  <TR>
    <TH align=left><FONT size=-1><A href="#Top"><IMG border=0 height=9 
      hspace=5 src="/icons/toc/uarrow.gif" width=11> Top</A> <BR><IMG border=0 
      height=9 hspace=5 src="/icons/toc/dot.gif" width=11><FONT color=#464c53> 
      Abstract</FONT> <BR><A href="#Introduction"><IMG border=0 height=9 
      hspace=5 src="/icons/toc/darrow.gif" width=11> Introduction</A> <BR><A 
      href="#MaterialsMethods"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/darrow.gif" width=11> Materials and Methods</A> <BR><A 
      href="#Results"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/darrow.gif" width=11> Results</A> <BR><A 
      href="#Discussion"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/darrow.gif" width=11> Discussion</A> <BR><A 
      href="#References"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/darrow.gif" width=11> References</A> 
</FONT></TH></TR></TBODY></TABLE>
<P><IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-Catenin is a 
cytoplasmic protein that participates in the assembly of cell-cell adherens 
junctions by binding cadherins to the actin cytoskeleton. In 
addition, it is a key component of the Wnt signaling pathway. 
Activation of this pathway triggers the accumulation of <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin in the 
nucleus, where it activates the transcription of target genes. 
Abnormal accumulation of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin is characteristic of 
various types of cancer and is caused by mutations either in the 
adenomatous polyposis coli protein, which regulates <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin degradation, or in the 
<IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
molecule itself. Aberrant accumulation of <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin in tumors is often 
associated with mutational inactivation of the p53 tumor suppressor. 
Here we show that overexpression of wild-type p53, by either 
transfection or DNA damage, down-regulates <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin in human and mouse 
cells. This effect was not obtained with transcriptionally inactive 
p53, including a common tumor-associated p53 mutant. The 
reduction in <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin level was accompanied by inhibition of 
its transactivation potential. The inhibitory effect of p53 on <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin is 
apparently mediated by the ubiquitin-proteasome system and requires 
an active glycogen synthase kinase 3<IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif"> (GSK3<IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">). Mutations in the N terminus of 
<IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin which 
compromise its degradation by the proteasomes, overexpression of 
dominant-negative <IMG align=bottom alt="Delta " 
src="/math/12pt/normal/Delta.gif">F-<IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-TrCP, or inhibition of GSK<IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif"> activity all rendered 
<IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
resistant to down-regulation by p53. These findings support the 
notion that there will be a selective pressure for the loss of 
wild-type p53 expression in cancers that are driven by excessive 
accumulation of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin. </P><TXT><A name=SEC0><!-- comment for mosaic --></A><BR clear=all><A name=Introduction><!-- null --></A>
<TABLE bgColor=#e1e1e1 cellPadding=0 cellSpacing=0 width="100%">
  <TBODY>
  <TR>
    <TD align=left bgColor=#ffffff vAlign=center width="5%">&nbsp;<IMG alt="" 
      height=21 hspace=5 src="/icons/toc/rarrow.gif" width=10></TD>
    <TH align=left vAlign=center width="95%"><FONT 
      size=+2>&nbsp;&nbsp;INTRODUCTION</FONT></TH></TR></TBODY></TABLE>
<TABLE align=right border=1 cellPadding=5 NOWRAP><R>
  <TBODY>
  <TR>
    <TH align=left><FONT size=-1><A href="#Top"><IMG border=0 height=9 
      hspace=5 src="/icons/toc/uarrow.gif" width=11> Top</A> <BR><A 
      href="#Abstract"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/uarrow.gif" width=11> Abstract</A> <BR><IMG border=0 
      height=9 hspace=5 src="/icons/toc/dot.gif" width=11><FONT color=#464c53> 
      Introduction</FONT> <BR><A href="#MaterialsMethods"><IMG border=0 height=9 
      hspace=5 src="/icons/toc/darrow.gif" width=11> Materials and Methods</A> 
      <BR><A href="#Results"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/darrow.gif" width=11> Results</A> <BR><A 
      href="#Discussion"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/darrow.gif" width=11> Discussion</A> <BR><A 
      href="#References"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/darrow.gif" width=11> References</A> 
</FONT></TH></TR></TBODY></TABLE>
<P><IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-Catenin plays 
a dual role in cells as a major structural component of cell-cell adherens 
junctions and as a pivotal signaling molecule in the Wnt pathway, 
transmitting transcriptional cues into the nucleus. In adherens 
junctions, <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin bridges between cadherin 
and the actin cytoskeleton through an interaction with <IMG 
align=bottom alt="alpha " src="/math/12pt/normal/alpha.gif">-catenin (<A 
href="#B2">2</A>, <A href="#B10">10</A>). Either the nonjunctional pool of <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin is 
degraded by the ubiquitin-proteasome system or, under certain 
conditions, <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin enters the nucleus and, together with 
lymphoid enhancer factor/T-cell factor transcription factors (<A 
href="#B9">9</A>, <A href="#B34">34</A>, <A href="#B56">56</A>), 
activates transcription by providing the transactivation domain to 
this heterodimeric complex (<A href="#B82">82</A>). The targeting of 
<IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin to 
the proteasome is achieved primarily through its phosphorylation by a 
multimolecular complex consisting of glycogen synthase kinase 3<IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif"> (GSK3<IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">), the adenomatous 
polyposis coli (APC) tumor suppressor protein, and axin (<A 
href="#B38">38</A>). The phosphoserine motif in the N terminus of 
<IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin (<A 
href="#B91">91</A>) is recognized by <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-TrCP, an F-box component of the E3 
ubiquitin ligase complex SCF<IMG align=bottom alt="beta " 
src="/math/12pt/normal/scr/beta.gif">TrCP (<A href="#B29">29</A>, <A 
href="#B41">41</A>, <A href="#B46">46</A>, <A href="#B71">71</A>, <A 
href="#B88">88</A>). Activation of the Wnt/wg signaling pathway leads 
to inhibition of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin degradation by decreasing 
the ability of GSK3<IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif"> to phosphorylate <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin. This reduces its 
susceptibility to degradation by the ubiquitin-proteasome system, 
leading to its accumulation (<A href="#B93">93</A>). </P>
<P>Studies in recent years have suggested that <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin is a potent oncogene product (<A 
href="#B64">64</A>), and its accumulation has been implicated in 
tumorigenesis in a wide variety of human cancers (<A href="#B65">65</A>, <A 
href="#B66">66</A>, <A href="#B94">94</A>). In colorectal cancer 
(CRC) the increase in <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin level is attributed to 
mutations in APC, which occur in about 80% of such tumors (<A 
href="#B55">55</A>, <A href="#B65">65</A>). Accumulation of <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin can also be 
triggered by mutations in the <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin gene itself, affecting the 
amino-terminal region of the protein that contains the GSK3<IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif"> phosphorylation sites 
(<A href="#B57">57</A>, <A href="#B70">70</A>). Such mutations are frequent 
in colon cancers retaining a wild-type (wt) APC gene (<A 
href="#B66">66</A>) and are also prevalent in melanoma, 
hepatocellular carcinoma (HCC), and a variety of other tumors (<A 
href="#B13">13</A>, <A href="#B16">16</A>, <A href="#B22">22-24</A>, <A 
href="#B36">36</A>, <A href="#B42">42</A>, <A href="#B43">43</A>, <A 
href="#B54">54</A>, <A href="#B70">70</A>, <A href="#B83">83</A>, <A 
href="#B87">87</A>, <A href="#B89">89</A>, <A href="#B95">95</A>). </P>
<P>The mechanism responsible for <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin-associated tumorigenesis is suggested 
to involve <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin- and LEF-1/TCF-activated 
genes, including genes that control the cell cycle (such as those 
for cyclin D1 [<A href="#B73">73</A>, <A href="#B80">80</A>] and c-myc [<A 
href="#B32">32</A>]), genes that are involved in cell-extracellular 
matrix interactions (such as those for matrilysin [<A 
href="#B14">14</A>], fibronectin [<A href="#B26">26</A>], and WISP-1 [<A 
href="#B90">90</A>]), and genes for various transcription factors, 
including Tcf-1 (<A href="#B68">68</A>), c-jun and fra-1 (<A 
href="#B48">48</A>), and PPAR<IMG align=bottom alt="delta " 
src="/math/12pt/normal/delta.gif"> (<A href="#B31">31</A>). The oncogenic role 
of <IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
is also supported by studies showing that introduction of mutant 
APC, or <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin, into transgenic mice results in 
enhanced tumor formation (<A href="#B25">25</A>, <A 
href="#B27">27</A>, <A href="#B63">63</A>). </P>
<P>Another protein which is implicated in many types of cancer is p53. Mutations 
in the p53 gene are found in about 50% of human cancers (reviewed in 
references <A href="#B45">45</A> and <A href="#B61">61</A>). Under normal 
conditions, p53 is most probably latent, owing to its rapid 
ubiquitination and proteolytic degradation. Mdm2, an oncoprotein 
possessing E3 ubiquitin ligase activity, plays a major role in this 
process (<A href="#B5">5</A>, <A href="#B61">61</A>). A variety of 
conditions can lead to the rapid stabilization and activation of p53. 
These include damage to DNA or to the mitotic spindle, ribonucleotide 
depletion, hypoxia, heat shock, and exposure to nitric oxide (<A 
href="#B4">4</A>, <A href="#B35">35</A>, <A href="#B45">45</A>, <A 
href="#B61">61</A>). In addition, p53 is induced by several oncogenic 
proteins, such as myc, ras, and adenovirus E1A, providing a direct 
link between oncogenic processes and the tumor suppressor action of 
p53 (reviewed in references <A href="#B3">3</A>, <A href="#B35">35</A>, 
<A href="#B45">45</A>, and <A href="#B61">61</A>). The activation of p53 
by these proteins relies mainly on ARF, a tumor suppressor protein 
that binds to Mdm2 and suppresses its p53 ubiquitination activity, 
thereby inhibiting p53 degradation (<A href="#B72">72</A>). Activated 
p53 can affect the cell cycle, apoptosis, senescence, DNA repair, 
cell differentiation, and angiogenesis (<A href="#B35">35</A>, <A 
href="#B76">76</A>), mostly via its function as a transcription factor 
that activates a number of target genes and by its interaction 
with a variety of proteins. Some of the better-studied p53 target 
genes are those for p21 (WAF1), which is mainly involved in 
G<SUB>1</SUB> arrest; GADD45 and 14-3-3<IMG align=bottom alt="sigma " 
src="/math/12pt/normal/sigma.gif">, which contribute to G<SUB>2</SUB> arrest; 
and BAX, Fas (APO1), PIG3, and KILLER (DR5), which lead to 
caspase activation and apoptosis (<A href="#B12">12</A>, <A 
href="#B18">18</A>). </P>
<P>A possible cross talk between p53 and <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin is suggested by the observation that 
cancers accumulating <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin (as a result of APC 
mutations) also exhibit a high frequency of p53 mutations, which was 
first illustrated by the analysis of human CRC (<A 
href="#B40">40</A>). Direct evidence for a cross talk between <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin and p53 was 
recently provided by studies demonstrating that excess <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin can induce an 
accumulation of active p53 (<A href="#B15">15</A>). This may explain, 
at least in part, the selective pressure for loss of p53 activity in 
tumors harboring deregulated <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin, such as CRC and 
HCC. </P>
<P>To elucidate why retention of functional p53 is disadvantageous to such 
tumors, we studied the effect of p53 on the level and transcriptional 
activity of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin. We report here that 
elevated levels of wt p53 down-regulate <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin in a variety of cell types. 
This down-regulation depends on the integrity and functionality of 
p53 and is not observed with a common tumor-associated p53 mutant. 
Moreover, this effect of p53 is exerted on wt <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin but not on the stable S33Y 
<IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin mutant, 
and it is blocked by the proteasome inhibitor MG132, a 
dominant-negative component of the E3 ubiquitin ligase complex <IMG 
align=bottom alt="Delta " src="/math/12pt/normal/Delta.gif">F-<IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-TrCP, and by LiCl, which 
inhibits GSK3<IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif"> activity. Furthermore, p53 can lead to a 
decrease in the level of the endogenous wt <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin in SW480 cells but 
not in that of the <IMG align=bottom alt="Delta " 
src="/math/12pt/normal/Delta.gif">S45 <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin mutant of HCT116 cells. Together 
with the observations of Damalas et al. (<A href="#B15">15</A>), our 
findings outline a negative feedback control involving <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin and p53, 
where excess <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin induces the accumulation of p53, while 
high p53 levels down-regulate <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin. Disruption of this feedback loop 
likely affects tumorigenesis driven by deregulated <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin activity and 
may therefore underlie the high frequency of p53 inactivation 
observed in CRC, HCC, and probably other types of cancer. 
</P><BR clear=all><A name=MaterialsMethods><!-- null --></A>
<TABLE bgColor=#e1e1e1 cellPadding=0 cellSpacing=0 width="100%">
  <TBODY>
  <TR>
    <TD align=left bgColor=#ffffff vAlign=center width="5%">&nbsp;<IMG alt="" 
      height=21 hspace=5 src="/icons/toc/rarrow.gif" width=10></TD>
    <TH align=left vAlign=center width="95%"><FONT 
      size=+2>&nbsp;&nbsp;MATERIALS AND METHODS</FONT></TH></TR></TBODY></TABLE>
<TABLE align=right border=1 cellPadding=5 NOWRAP><R>
  <TBODY>
  <TR>
    <TH align=left><FONT size=-1><A href="#Top"><IMG border=0 height=9 
      hspace=5 src="/icons/toc/uarrow.gif" width=11> Top</A> <BR><A 
      href="#Abstract"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/uarrow.gif" width=11> Abstract</A> <BR><A 
      href="#Introduction"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/uarrow.gif" width=11> Introduction</A> <BR><IMG border=0 
      height=9 hspace=5 src="/icons/toc/dot.gif" width=11><FONT color=#464c53> 
      Materials and Methods</FONT> <BR><A href="#Results"><IMG border=0 height=9 
      hspace=5 src="/icons/toc/darrow.gif" width=11> Results</A> <BR><A 
      href="#Discussion"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/darrow.gif" width=11> Discussion</A> <BR><A 
      href="#References"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/darrow.gif" width=11> References</A> 
</FONT></TH></TR></TBODY></TABLE>
<P align=left><B>Cells and transfections.</B> The HCT116 and SW480 human colon 
carcinoma cell lines, the human H1299 lung adenocarcinoma cell line, and the 
293&nbsp;adenovirus-transformed human embryo kidney cell line were 
cultured in Dulbecco's modified Eagle's medium supplemented with 10% 
bovine calf serum (BCS). wt mouse embryonal fibroblasts (MEF), 
p53<IMG align=bottom alt=- src="/math/12pt/normal/scr/minus.gif">/<IMG 
align=bottom alt=- src="/math/12pt/normal/scr/minus.gif"> MEF, and 
double-mutant p53<IMG align=bottom alt=- 
src="/math/12pt/normal/scr/minus.gif">/<IMG align=bottom alt=- 
src="/math/12pt/normal/scr/minus.gif"> Mdm2<IMG align=bottom alt=- 
src="/math/12pt/normal/scr/minus.gif">/<IMG align=bottom alt=- 
src="/math/12pt/normal/scr/minus.gif"> MEF (<A href="#B15">15</A>) were 
cultured in Dulbecco's modified Eagle's medium plus 10% BCS, 
100&nbsp;ÂµM nonessential amino acid mixture (Biological Industries 
Israel), and 50&nbsp;ÂµM <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-mercaptoethanol. WI38 normal human 
embryonic lung fibroblasts were cultured in minimum essential 
medium with 20% BCS. For transfections, cells were plated to form 
a 50&nbsp;to 70% confluent culture in a 30-mm-diameter dish. The 
SW480 and HCT116 cell lines were transfected using Lipofectamine 
(GIBCO BRL), while the 293&nbsp;cells were transfected by the calcium 
phosphate method. The treatment with 30&nbsp;mM LiCl in some 
experiments was overnight, the treatment with 10&nbsp;ÂµM MG132 was 
for 4&nbsp;h, and the treatment with 5&nbsp;Âµg of doxorubicin (DOX) 
per ml or 5&nbsp;Âµg of cisplatin per ml was for periods ranging from 
2&nbsp;to 48&nbsp;h. </P>
<P align=left><B>Plasmids.</B> The following expression plasmids encoding 
various p53 constructs were employed: mouse wt p53 (<A href="#B20">20</A>), 
mouse mutant p53<IMG align=bottom alt="Delta " 
src="/math/12pt/normal/Delta.gif">13-52 (<A href="#B30">30</A>), 
hemagglutinin (HA)-tagged human p53 (HA-p53) (<A href="#B50">50</A>), human 
wt p53 (<A href="#B7">7</A>), and the human R175H mutant p53 (<A 
href="#B7">7</A>, <A href="#B60">60</A>). The reporter plasmid 
containing the cyclin G promoter-luciferase (<A href="#B30">30</A>), 
the LEF/TCF reporter plasmids TOPFLASH and FOPFLASH (<A 
href="#B82">82</A>), the <IMG align=bottom alt="Delta " 
src="/math/12pt/normal/Delta.gif">F-<IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-TrCP-expressing plasmid (<A 
href="#B71">71</A>), and the vectors expressing various <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin forms 
(HA-<IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin, 
HA-S33Y <IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin, 
and vesicular stomatitis virus [VSV]-<IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin) (<A href="#B73">73</A>, <A 
href="#B74">74</A>, <A href="#B93">93</A>) were as described 
previously. </P>
<P align=left><B>Protein analysis.</B> Protein levels were monitored by Western 
blotting. The following antibodies were used. Polyclonal anti-<IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin and monoclonal 
antivinculin were from Sigma; monoclonal anti-<IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin (clone 
14c19220) was from Transduction Laboratories. The 14c19220 antibody 
was generated against amino acids 571&nbsp;to 781&nbsp;and recognizes 
the caspase-cleaved 65-kDa product of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin (<A href="#B11">11</A>, <A 
href="#B81">81</A>). Monoclonal antibodies against p53 included 
anti-human p53 DO1 (<A href="#B84">84</A>), PAb1801 (<A 
href="#B8">8</A>), anti-mouse p53 (which cross-reacts with human p53), and 
PAb421 (<A href="#B28">28</A>). A polyclonal anti-p53 was kindly provided 
by Varda Rotter, Weizmann Institute of Science). Monoclonal anti-HA 
clone 12CA5 way from Boehringer Mannheim), and polyclonal anti-HA 
Y11 sc-805 was from Santa Cruz Biotechnology. Fractionation of 
proteins into Triton X-100-soluble and -insoluble fractions was 
performed as previously described (<A href="#B71">71</A>), and equal 
volumes of lysates from the two fractions were analyzed by Western 
blotting. Western blots were developed using the ECL method 
(Amersham). Autoradiograms were scanned with a GS-700 imaging 
densitometer (Bio-Rad Laboratories) using the FotoLook PS 
2.07.2&nbsp;software. The intensity of the bands was quantitated 
using the NIH image 1.61&nbsp;software. </P>
<P align=left><B>Luciferase assay</B> For transactivation assays, 1&nbsp;Âµg of 
luciferase reporter plasmid was cotransfected with 2&nbsp;Âµg of the <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin construct 
and 2&nbsp;Âµg of the various p53 constructs, as indicated. A <IMG 
align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-galactosidase-expressing vector was 
included as an internal control for transfection efficiency. After 
24&nbsp;h, the cells were lysed and both luciferase and <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-galactosidase 
activities were determined with enzyme assay kits (Promega). 
Luminescence was quantitated using a TD-20e luminometer (Turner 
Design) from duplicate plates. The results represent data from at 
least five independent experiments. </P>
<P align=left><B>Immunofluorescence microscopy</B> Cells were cultured on glass 
coverslips, fixed with 3% paraformaldehyde in phosphate-buffered saline, and 
permeabilized with 0.5% Triton X-100. The coverslips were incubated 
with the primary antibodies as described above. The secondary 
antibodies were Alexa 488-conjugated goat anti-mouse or anti-rabbit 
immunoglobulin G (Molecular Probes) and Cy3-conjugated goat 
anti-mouse or anti-rabbit immunoglobulin G (Jackson ImmunoResearch 
Laboratories). Images were acquired using the DeltaVision system 
(Applied Precision) equipped with a Zeiss (Oberkochen, Germany) 
Axiovert 100&nbsp;microscope and a Photometrics (Tucson, Ariz.) 
300&nbsp;series scientific-grade cooled charge-coupled device camera 
(reading 12-bit images), using a 100Ã, 1.3&nbsp;numerical-aperture 
plan-Neofluar objective (Zeiss). For quantitative image processing, 
the Priism software was employed (<A href="#B37">37</A>). At least 
50&nbsp;transfected and 50&nbsp;nontransfected cells were examined in 
each experiment. </P><BR clear=all><A name=Results><!-- null --></A>
<TABLE bgColor=#e1e1e1 cellPadding=0 cellSpacing=0 width="100%">
  <TBODY>
  <TR>
    <TD align=left bgColor=#ffffff vAlign=center width="5%">&nbsp;<IMG alt="" 
      height=21 hspace=5 src="/icons/toc/rarrow.gif" width=10></TD>
    <TH align=left vAlign=center width="95%"><FONT 
      size=+2>&nbsp;&nbsp;RESULTS</FONT></TH></TR></TBODY></TABLE>
<TABLE align=right border=1 cellPadding=5 NOWRAP><R>
  <TBODY>
  <TR>
    <TH align=left><FONT size=-1><A href="#Top"><IMG border=0 height=9 
      hspace=5 src="/icons/toc/uarrow.gif" width=11> Top</A> <BR><A 
      href="#Abstract"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/uarrow.gif" width=11> Abstract</A> <BR><A 
      href="#Introduction"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/uarrow.gif" width=11> Introduction</A> <BR><A 
      href="#MaterialsMethods"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/uarrow.gif" width=11> Materials and Methods</A> <BR><IMG 
      border=0 height=9 hspace=5 src="/icons/toc/dot.gif" width=11><FONT 
      color=#464c53> Results</FONT> <BR><A href="#Discussion"><IMG border=0 
      height=9 hspace=5 src="/icons/toc/darrow.gif" width=11> Discussion</A> 
      <BR><A href="#References"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/darrow.gif" width=11> References</A> 
</FONT></TH></TR></TBODY></TABLE>
<P align=left><B>Excess p53 reduces <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin protein levels</B> Since recent 
studies have shown that excess <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin can promote the accumulation of p53 
(<A href="#B15">15</A>), we examined the possibility that there is a 
reciprocal relationship between p53 and <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin. We have addressed this 
question by monitoring the level of endogenous <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin in cells in which p53 was 
induced by DNA damage. MEF from wt mice (p53+/+) and from 
p53 knockout mice (p53<IMG align=bottom alt=- 
src="/math/12pt/normal/scr/minus.gif">/<IMG align=bottom alt=- 
src="/math/12pt/normal/scr/minus.gif">) were treated for 24&nbsp;h with 
5&nbsp;Âµg of DOX per ml, which effectively induces p53 stabilization 
and accumulation (<A href="#B4">4</A>). DOX treatment elicited a 
strong nuclear p53 accumulation in the p53+/+ MEF (Fig. <A 
href="#F1">1</A>C; compare to Fig. <A href="#F1">1</A>A). <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-Catenin was present in the 
cytoplasm and adherens junctions in both p53+/+ and 
p53<IMG align=bottom alt=- src="/math/12pt/normal/scr/minus.gif">/<IMG 
align=bottom alt=- src="/math/12pt/normal/scr/minus.gif"> cells before DOX 
treatment (Fig. <A href="#F1">1</A>B and F), but following DOX 
treatment, adherens junctions were disrupted in both cell types 
(Fig. <A href="#F1">1</A>D and H). However, while in p53<IMG 
align=bottom alt=- src="/math/12pt/normal/scr/minus.gif">/<IMG align=bottom 
alt=- src="/math/12pt/normal/scr/minus.gif"> MEF the intensity of <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin staining 
remained unchanged and the protein was strongly visible in the 
cytoplasm and at the edges of the disrupted junctions (Fig. <A 
href="#F1">1</A>H), in p53+/+ MEF <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin staining was significantly reduced in 
the majority of cells (Fig. <A href="#F1">1</A>D). During the 
24&nbsp;h of DOX treatment, no morphological signs of apoptosis were 
observed in these cells (Fig. <A href="#F1">1</A>C, D, G, and H and 
data not shown).To quantify the effect of p53 on <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin levels, cell lysates 
isolated after 0,&nbsp;2,&nbsp;8,&nbsp;16,&nbsp;and 24&nbsp;h of DOX 
treatment were immunoblotted with anti-<IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin antibody. To distinguish 
between free cytosolic and cytoskeletal or nuclear <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin, cells were fractionated 
into Triton X-100-soluble and Triton X-insoluble pools (Fig. <A 
href="#F2">2</A>A). In p53+/+ MEF, p53 levels peaked at 16&nbsp;h 
after DOX treatment and declined at later times (Fig. <A 
href="#F2">2</A>A). This p53 was largely Triton insoluble, reflecting 
its nuclear accumulation. <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-Catenin, in both the Triton 
X-100-soluble and -insoluble fractions, decreased considerably 
after 24&nbsp;h of DOX treatment (Fig. <A href="#F2">2</A>A and A'), while 
no significant decrease in the vinculin level was observed under 
these conditions (Fig. <A href="#F2">2</A>A and A'). In contrast, in 
p53<IMG align=bottom alt=- src="/math/12pt/normal/scr/minus.gif">/<IMG 
align=bottom alt=- src="/math/12pt/normal/scr/minus.gif"> MEF neither <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin nor vinculin 
levels decreased following DOX treatment (Fig. <A href="#F2">2</A>B 
and B'). When p53 expression was induced by cisplatin treatment of 
p53+/+ MEF (Fig. <A href="#F2">2</A>C), a comparable decrease in <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin was 
observed (Fig. 2C'). Cisplatin did not induce a detectable change in 
<IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
levels of p53<IMG align=bottom alt=- 
src="/math/12pt/normal/scr/minus.gif">/<IMG align=bottom alt=- 
src="/math/12pt/normal/scr/minus.gif"> MEF (Fig. <A href="#F2">2</A>D and 
D'). The effect of p53 on <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin was also observed in normal 
WI38 human embryonic lung fibroblasts (Fig. <A href="#F2">2</A>E). 
p53 was strongly induced in these cells after DOX treatment, and its 
localization shifted from the Triton X-100-soluble to the 
Triton-insoluble fraction, probably reflecting its translocation from 
the cytoplasm to the nucleus. In these cells, treatment with DOX for 
48&nbsp;h induced a fivefold reduction in the Triton X-100-soluble 
<IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
(Fig. 2E'), while the Triton X-100-insoluble fraction was only 
moderately affected (Fig. <A href="#F2">2</A>E and E'). In contrast, the 
levels of vinculin in the Triton X-100-soluble fraction of these 
cells did not change significantly (Fig. <A href="#F2">2</A>E and E'). 
Immunofluorescence analysis of WI38 cells treated with DOX for 
24&nbsp;or 48&nbsp;h revealed intact nuclei and well-spread cells 
(data not shown), implying that the DOX treatment did not induce 
apoptosis in these cells. <A name=F1><!-- FIG 1 --></A><BR clear=all>
<P>
<CENTER>
<TABLE border=1 cellPadding=0 cellSpacing=0 width="95%">
  <TBODY>
  <TR bgColor=#e1e1e1>
    <TD>
      <TABLE cellPadding=2 cellSpacing=2>
        <TBODY>
        <TR bgColor=#e1e1e1>
          <TD align=middle bgColor=#ffffff vAlign=top><A 
            href="/cgi/content/full/21/20/6768/F1"><IMG border=2 height=146 
            hspace=10 src="/content/vol21/issue20/images/small/mb2010174001.gif" 
            vspace=5 width=200></A><BR><STRONG>View larger version</STRONG> 
            (102K): <BR><NOBR><A href="/cgi/content/full/21/20/6768/F1">[in this 
            window]</A> <BR><A href="/cgi/content-nw/full/21/20/6768/F1" 
            onclick="startTarget('F1', 590, 521); this.href='/cgi/content-nw/full/21/20/6768/F1'" 
            onmouseover="window.status='View figure in a separate window'; return true" 
            target=F1>[in a new window]</A><BR>&nbsp; </NOBR></TD>
          <TD align=left vAlign=top><STRONG>FIG. 1. &nbsp;</STRONG> Effect of 
            DOX-induced p53 expression on <IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-catenin organization and level. 
            MEF cells were plated on coverslips, treated with 5&nbsp;Âµg of DOX 
            per ml for 24&nbsp;h, fixed, and double stained for p53 using an 
            anti-mouse p53 polyclonal antibody (A, C, E, and G) and for <IMG 
            align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
            (<IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-cat) using a monoclonal anti-<IMG 
            align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
            antibody (B, D, F, and H). Bar, 10&nbsp;Âµm. <BR 
        clear=left></TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER><!-- /FIG 1 --><A 
name=F2><!-- FIG 2 --></A><BR clear=all>
<P>
<CENTER>
<TABLE border=1 cellPadding=0 cellSpacing=0 width="95%">
  <TBODY>
  <TR bgColor=#e1e1e1>
    <TD>
      <TABLE cellPadding=2 cellSpacing=2>
        <TBODY>
        <TR bgColor=#e1e1e1>
          <TD align=middle bgColor=#ffffff vAlign=top><A 
            href="/cgi/content/full/21/20/6768/F2"><IMG border=2 height=200 
            hspace=10 src="/content/vol21/issue20/images/small/mb2010174002.gif" 
            vspace=5 width=107></A><BR><STRONG>View larger version</STRONG> 
            (24K): <BR><NOBR><A href="/cgi/content/full/21/20/6768/F2">[in this 
            window]</A> <BR><A href="/cgi/content-nw/full/21/20/6768/F2" 
            onclick="startTarget('F2', 385, 640); this.href='/cgi/content-nw/full/21/20/6768/F2'" 
            onmouseover="window.status='View figure in a separate window'; return true" 
            target=F2>[in a new window]</A><BR>&nbsp; </NOBR></TD>
          <TD align=left vAlign=top><STRONG>FIG. 2. &nbsp;</STRONG> Effect of 
            p53 elevation on <IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-catenin levels in the Triton 
            X-100-soluble and -insoluble fractions of different cell types. 
            Cells were treated with 5&nbsp;Âµg of DOX per ml (A and B) or 
            5&nbsp;Âµg of cisplatin per ml (C and D) for the indicated time 
            periods. Proteins were fractionated into Triton X-100-soluble (lanes 
            s) and -insoluble (lanes i) fractions, resolved by sodium dodecyl 
            sulfate-polyacrylamide gel electrophoresis, and subjected to Western 
            blot analysis using the antibodies indicated in the legend to Fig. 
            <A href="#F1">1</A> and with an antivinculin (vin) antibody. The 
            intensities of the bands from representative gels of MEF 
            p53+/+ (A and C) and MEF p53<IMG align=bottom alt=- 
            src="/math/12pt/normal/scr/minus.gif">/<IMG align=bottom alt=- 
            src="/math/12pt/normal/scr/minus.gif"> (B and D) cells were 
            quantified and plotted (A', C', B', and D', respectively). Extracts 
            from WI38 cells (E and E') were blotted with the monoclonal 
            anti-<IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-catenin antibody (<IMG 
            align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-cat), 
            vinculin (vin), and a mixture of the anti-human p53 antibodies DO1 
            and 1801&nbsp;and analyzed as described for MEF cells. a.u., 
            arbitrary units. <BR 
clear=left></TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER><!-- /FIG 2 -->
<P></P>The ability of excess p53 to reduce <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin levels was also observed in 
293&nbsp;cells transfected with a p53 expression plasmid (Fig. <A 
href="#F3">3</A>). Transfection of p53 into these cells resulted in a major 
decrease in the level of endogenous Triton X-100-soluble <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin (which is 
believed to represent the signaling pool of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin) but not in that of 
vinculin (Fig. <A href="#F3">3</A>A). To determine whether p53 can 
also affect the signaling activity of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin, p53 and <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin were cotransfected into 
293&nbsp;cells together with the LEF-1 reporter plasmid TOPFLASH (<A 
href="#B82">82</A>) or with a variety of control plasmids. The 
transfected p53 was transcriptionally active as seen from its ability 
to strongly activate the p53-responsive cyclin G promoter (Fig. <A 
href="#F3">3</A>B, bars 1&nbsp;and 2). The cytomegalovirus promoter, a 
target for nonspecific repression by high levels of p53 (<A 
href="#B78">78</A>), was repressed only slightly under these 
conditions (Fig. <A href="#F3">3</A>B, bars 3&nbsp;and 4), while p53 
had no effect on the control FOPFLASH reporter plasmid (Fig. <A 
href="#F3">3</A>B, bars 6&nbsp;and 8). In contrast, p53 very strongly 
suppressed the <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin-mediated luciferase activity driven 
from the TOPFLASH reporter (Fig. <A href="#F3">3</A>B, bars 
11&nbsp;and 12). Analysis of protein levels revealed that in these 
cotransfected 293&nbsp;cells, p53 caused a dramatic reduction in the 
steady-state <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin levels (Fig. <A href="#F3">3</A>C). In 
contrast, the levels of the closely related HA-plakoglobin protein 
(<A href="#B94">94</A>), transduced with the same expression vector, 
were not affected by p53 (Fig. <A href="#F3">3</A>C). This specific 
down-regulation of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin is likely responsible for 
the inhibitory effect of p53 on <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin-dependent transcriptional 
activity. <A name=F3><!-- FIG 3 --></A><BR clear=all>
<P>
<CENTER>
<TABLE border=1 cellPadding=0 cellSpacing=0 width="95%">
  <TBODY>
  <TR bgColor=#e1e1e1>
    <TD>
      <TABLE cellPadding=2 cellSpacing=2>
        <TBODY>
        <TR bgColor=#e1e1e1>
          <TD align=middle bgColor=#ffffff vAlign=top><A 
            href="/cgi/content/full/21/20/6768/F3"><IMG border=2 height=200 
            hspace=10 src="/content/vol21/issue20/images/small/mb2010174003.gif" 
            vspace=5 width=180></A><BR><STRONG>View larger version</STRONG> 
            (31K): <BR><NOBR><A href="/cgi/content/full/21/20/6768/F3">[in this 
            window]</A> <BR><A href="/cgi/content-nw/full/21/20/6768/F3" 
            onclick="startTarget('F3', 546, 640); this.href='/cgi/content-nw/full/21/20/6768/F3'" 
            onmouseover="window.status='View figure in a separate window'; return true" 
            target=F3>[in a new window]</A><BR>&nbsp; </NOBR></TD>
          <TD align=left vAlign=top><STRONG>FIG. 3. &nbsp;</STRONG> Reciprocal 
            effects of p53 and <IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-catenin overexpression on the 
            levels of these proteins and the transcriptional activity of <IMG 
            align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin. 
            (A) p53 or a control empty vector was transfected into 
            293&nbsp;cells. After 20&nbsp;h, cells were fractionated into Triton 
            X-100-soluble (lanes s) and -insoluble (lanes i) fractions and 
            subjected to Western blot analysis. The positions of <IMG 
            align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
            (<IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-cat), p53, and vinculin (vin) are 
            marked. (B) Transactivation assays with reporter plasmids expressing 
            luciferase under the transcriptional control of different promoters 
            in the presence of p53 and <IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-catenin. Bars 1&nbsp;and 
            2,&nbsp;cyclin G (CycG) promoter; bars 3&nbsp;and 
            4,&nbsp;cytomegalovirus promoter; bars 5&nbsp;to 8,&nbsp;FOPFLASH; 
            bars 9&nbsp;to 12,&nbsp;TOPFLASH. Cells were collected 20&nbsp;h 
            after transfection and subjected to luciferase and <IMG align=bottom 
            alt="beta " src="/math/12pt/normal/beta.gif">-galactosidase assays. 
            The standard error is indicated. (C) Effect of transfected p53 on 
            the levels of cotransfected HA-<IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-catenin or HA-plakoglobin (PG) 
            blotted with anti-HA antibody. The positions of <IMG align=bottom 
            alt="beta " src="/math/12pt/normal/beta.gif">-catenin, plakoglobin, 
            and p53 are indicated. (D) H1299 cells (which are p53 deficient) 
            were transfected with increasing amounts of HA-<IMG align=bottom 
            alt="beta " src="/math/12pt/normal/beta.gif">-catenin (0&nbsp;to 
            4&nbsp;Âµg) and a constant amount of p53 (100&nbsp;ng) (lanes 
            1&nbsp;to 3) or with a constant amount of HA-<IMG align=bottom 
            alt="beta " src="/math/12pt/normal/beta.gif">-catenin (4&nbsp;Âµg) 
            and increasing amounts of p53 (0&nbsp;to 600&nbsp;ng) (lanes 
            4&nbsp;to 7). The levels of HA-<IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-catenin (<IMG align=bottom 
            alt="beta " src="/math/12pt/normal/beta.gif">-cat) and p53 were 
            determined by Western blot analysis. The endogenous vinculin served 
            as loading control. <BR 
clear=left></TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER><!-- /FIG 3 -->
<P></P>
<P align=left><B>Reciprocal relationship between <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin and p53 expression.</B> Since in a 
recent study we have shown that excess <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin can promote the accumulation of 
exogenously introduced p53 in H1299 cells (which lack p53) (<A 
href="#B15">15</A>), we wished to examine, in the same cellular 
system, the predicted reciprocal relationship between <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin and p53 
expression. The results shown in Fig. <A href="#F3">3</A>D clearly 
demonstrate that when a constant level of p53 was cotransfected into 
H1299 cells with increasing levels of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin, the increase in the 
expression of p53 was highest when high levels of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin were transfected (Fig. <A 
href="#F3">3</A>D, compare lanes 2&nbsp;and 3). In contrast, when a 
constant high level of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin was cotransfected with 
increasing amounts of p53, a decrease in the level of <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin was already 
apparent with the initial low level of p53 (Fig. <A href="#F3">3</A>D, 
lanes 4&nbsp;and 5), and a dramatic reduction in <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin was seen with 
the higher concentrations of p53 (Fig. <A href="#F3">3</A>D, lanes 4&nbsp;to 
7). Taken together, these results demonstrate the dose-dependent 
reciprocal relationship between <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin and p53 expression in the same 
cells and that p53 can reduce the levels and transcriptional activity 
of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin, irrespective of whether <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin is expressed 
from the endogenous gene or from an expression plasmid. 
</P>
<P align=left><B>p53 mutants fail to reduce <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin levels</B> Next, we examined the 
ability of mutant forms of p53 to down-regulate <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin. Unlike wt p53, which strongly reduced 
the levels and transcriptional activity of <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin in 293&nbsp;cells, 
the mouse p53 deletion mutant p53<IMG align=bottom alt="Delta " 
src="/math/12pt/normal/Delta.gif">13-52, which lacks transactivation 
and Mdm2 binding activities (the transactivation domain is only 
partially deleted but is apparently nonfunctional) (Fig. <A 
href="#F4">4</A>A), had no detectable effect on <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin level and 
transcriptional activity (Fig. <A href="#F4">4</A>B and C). 
Importantly, the cancer-associated hot spot human p53 mutant 
(p53R175H) (<A href="#B7">7</A>, <A href="#B60">60</A>) was also unable 
to down-regulate <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin (Fig <A href="#F4">4</A>D). The 
presence of Mdm2 was apparently not required for the p53-mediated 
reduction in <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin level, since in 
double-mutant MEF (deficient in both p53 and Mdm2), transfection of 
p53 was still capable of efficiently decreasing <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin expression (Fig. <A 
href="#F4">4</A>E). Hence, the integrity and functionality of p53 are 
required for its ability to down-regulate <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin and are apparently 
independent of Mdm2. <A name=F4><!-- FIG 4 --></A><BR clear=all>
<P>
<CENTER>
<TABLE border=1 cellPadding=0 cellSpacing=0 width="95%">
  <TBODY>
  <TR bgColor=#e1e1e1>
    <TD>
      <TABLE cellPadding=2 cellSpacing=2>
        <TBODY>
        <TR bgColor=#e1e1e1>
          <TD align=middle bgColor=#ffffff vAlign=top><A 
            href="/cgi/content/full/21/20/6768/F4"><IMG border=2 height=200 
            hspace=10 src="/content/vol21/issue20/images/small/mb2010174004.gif" 
            vspace=5 width=190></A><BR><STRONG>View larger version</STRONG> 
            (28K): <BR><NOBR><A href="/cgi/content/full/21/20/6768/F4">[in this 
            window]</A> <BR><A href="/cgi/content-nw/full/21/20/6768/F4" 
            onclick="startTarget('F4', 568, 640); this.href='/cgi/content-nw/full/21/20/6768/F4'" 
            onmouseover="window.status='View figure in a separate window'; return true" 
            target=F4>[in a new window]</A><BR>&nbsp; </NOBR></TD>
          <TD align=left vAlign=top><STRONG>FIG. 4. &nbsp;</STRONG> p53 
            mutants fail to reduce <IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-catenin (<IMG align=bottom 
            alt="beta " src="/math/12pt/normal/beta.gif">-cat) levels and 
            transactivation capacity. (A) Schematic representation of the 
            p53<IMG align=bottom alt="Delta " 
            src="/math/12pt/normal/Delta.gif">13-52 mutant. TAD, transactivation 
            domain. (B) Transactivation in 293&nbsp;cells, using the TOPFLASH 
            reporter plasmid transfected either alone (bar 1) or with HA-<IMG 
            align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
            (bars 2&nbsp;to 4) in the presence of wt mouse p53 (bar 3) or the 
            mutant <IMG align=bottom alt="Delta " 
            src="/math/12pt/normal/Delta.gif">13-52 mouse p53 (bar 4). Cells 
            were harvested 20&nbsp;h after transfection and subjected to 
            luciferase activity assay. The standard error is indicated. (C) 
            Western blot analysis for <IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-catenin, p53, and p53<IMG 
            align=bottom alt="Delta " src="/math/12pt/normal/Delta.gif">13-52 in 
            cell lysates from the experiment in panel B.&nbsp;(D) Human wt p53 
            or a human p53R175H mutant was cotransfected with HA-<IMG 
            align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
            into 293&nbsp;cells and subjected to Western blot analysis. (E) p53 
            can reduce the levels of <IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-catenin in Mdm2-deficient MEF. 
            p53<IMG align=bottom alt=- 
            src="/math/12pt/normal/scr/minus.gif">/<IMG align=bottom alt=- 
            src="/math/12pt/normal/scr/minus.gif"> Mdm2<IMG 
            align=bottom alt=- src="/math/12pt/normal/scr/minus.gif">/<IMG 
            align=bottom alt=- src="/math/12pt/normal/scr/minus.gif"> 
            double-mutant MEF were transfected with 5&nbsp;Âµg of <IMG 
            align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
            plasmid in the presence or absence of 300&nbsp;ng of p53 plasmid. 
            The level of the transfected (HA-tagged) <IMG align=bottom 
            alt="beta " src="/math/12pt/normal/beta.gif">-catenin was determined 
            by Western blot analysis. The positions of <IMG align=bottom 
            alt="beta " src="/math/12pt/normal/beta.gif">-catenin and p53 are 
            indicated. The asterisks in panels C, D, and E represent a 
            nonspecific band obtained with the anti-HA antibody. <BR 
          clear=left></TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER><!-- /FIG 4 -->
<P></P>
<P align=left><B>Involvement of GSK3<IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif"> and the proteasome system in p53-mediated 
down-regulation of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin.</B> The targeting of <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin to the 
proteasome is achieved through its phosphorylation by GSK3<IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif"> in a multiprotein complex, 
followed by its recognition by <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-TrCP, a component of the E3 ubiquitin 
ligase system (<A href="#B29">29</A>, <A href="#B41">41</A>, <A 
href="#B46">46</A>, <A href="#B71">71</A>, <A href="#B88">88</A>). To examine 
whether the reduction in <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin level by p53 requires the 
activity of GSK3<IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">, the effect of p53 on <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin in cells treated with 
LiCl, which inhibits the activity of GSK3<IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif"> (<A href="#B91">91</A>), was determined. 
As shown in Fig. <A href="#F5">5</A>A, incubation with LiCl blocked the 
ability of p53 to lower <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin levels (Fig. <A href="#F5">5</A>A, 
compare lanes 3&nbsp;and 4). The effect of p53 on cotransfected <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin was also 
blocked in the presence of the proteasome inhibitor MG132 (Fig. <A 
href="#F5">5</A>B, lanes 3&nbsp;and 4), implying that p53 promotes 
the degradation of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin through the proteasome 
system. Furthermore, p53 did not reduce the level of the S33Y mutant 
<IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin, which 
is relatively refractory to phosphorylation by GSK3<IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif"> and hence to proteasomal 
degradation (<A href="#B21">21</A>, <A href="#B29">29</A>, <A 
href="#B46">46</A>), in either the presence (Fig. <A href="#F5">5</A>B, lanes 
7&nbsp;and 8) or in the absence (Fig. <A href="#F5">5</A>B, lanes 
5&nbsp;and 6) of MG132. When HA-tagged ubiquitin was cotransfected 
with <IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin in 
the presence or absence of p53, an increase in ubiquitinated <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin was 
detected in immunoprecipitates obtained from cells overexpressing p53 
(data not shown). Further support for the notion that p53 
overexpression stimulates <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin degradation via the classical Wnt 
pathway was obtained from cotransfection of 293&nbsp;cells with <IMG 
align=bottom alt="Delta " src="/math/12pt/normal/Delta.gif">F-<IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-TrCP, which binds to 
serine-phosphorylated <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin and blocks its degradation 
(<A href="#B71">71</A>). As shown in Fig. <A href="#F5">5</A>C, expression of 
<IMG align=bottom alt="Delta " src="/math/12pt/normal/Delta.gif">F-<IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-TrCP 
partially blocked the p53-induced reduction in <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin levels. These 
results suggest that p53 can promote the turnover of <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin by augmenting 
its <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-TrCP-mediated proteasomal degradation and 
that typical oncogenic mutations of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin (such as the S33Y mutation) 
can render it resistant to high levels of p53. <A name=F5><!-- FIG 5 --></A><BR 
clear=all>
<P>
<CENTER>
<TABLE border=1 cellPadding=0 cellSpacing=0 width="95%">
  <TBODY>
  <TR bgColor=#e1e1e1>
    <TD>
      <TABLE cellPadding=2 cellSpacing=2>
        <TBODY>
        <TR bgColor=#e1e1e1>
          <TD align=middle bgColor=#ffffff vAlign=top><A 
            href="/cgi/content/full/21/20/6768/F5"><IMG border=2 height=200 
            hspace=10 src="/content/vol21/issue20/images/small/mb2010174005.gif" 
            vspace=5 width=129></A><BR><STRONG>View larger version</STRONG> 
            (26K): <BR><NOBR><A href="/cgi/content/full/21/20/6768/F5">[in this 
            window]</A> <BR><A href="/cgi/content-nw/full/21/20/6768/F5" 
            onclick="startTarget('F5', 433, 640); this.href='/cgi/content-nw/full/21/20/6768/F5'" 
            onmouseover="window.status='View figure in a separate window'; return true" 
            target=F5>[in a new window]</A><BR>&nbsp; </NOBR></TD>
          <TD align=left vAlign=top><STRONG>FIG. 5. &nbsp;</STRONG> Blocking 
            of GSK3<IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif"> activity, polyubiquitination, and 
            proteasomal degradation inhibit the effect of p53 on <IMG 
            align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
            (<IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-cat). (A) wt HA-<IMG align=bottom 
            alt="beta " src="/math/12pt/normal/beta.gif">-catenin was 
            transfected into 293&nbsp;cells with p53 (lanes 3&nbsp;and 4) or 
            without p53 (lanes 1&nbsp;and 2), and half of the cultures were 
            treated overnight with 30&nbsp;mM LiCl (lanes 2&nbsp;and 4) before 
            harvesting of the cells and determination of the levels of HA-<IMG 
            align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
            and p53 by Western blot analysis. (B) wt <IMG align=bottom 
            alt="beta " src="/math/12pt/normal/beta.gif">-catenin (lanes 
            1&nbsp;to 4) or the HA-S33Y <IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-catenin mutant (lanes 5&nbsp;to 8) 
            was cotransfected with p53 into 293&nbsp;cells. After 16&nbsp;h, 
            MG132 (25&nbsp;ÂµM) was added to the indicated samples (lanes 
            3,&nbsp;4,&nbsp;7,&nbsp;and 8). The cells were harvested 4&nbsp;h 
            later and subjected to Western blot analysis. The upper panel shows 
            the levels of <IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-catenin (wt or S33Y mutant). The 
            lower panel shows the transfected p53. (C) VSV-tagged <IMG 
            align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
            (1&nbsp;Âµg) was transfected alone (lane 1) or cotransfected with p53 
            (1&nbsp;Âµg) (lane 2) and increasing concentrations (2&nbsp;Âµg [lane 
            3] and 4&nbsp;Âµg [lane 4]) of the dominant-negative HA-tagged <IMG 
            align=bottom alt="Delta " src="/math/12pt/normal/Delta.gif">F-<IMG 
            align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-TrCP. The 
            transfected wt <IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-catenin was detected by anti-VSV 
            antibody, while <IMG align=bottom alt="Delta " 
            src="/math/12pt/normal/Delta.gif">F-<IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-TrCP expression was monitored with 
            an anti-HA tag antibody. The asterisk indicates a nonspecific band 
            obtained with the anti-HA antibody. <BR 
      clear=left></TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER><!-- /FIG 5 -->
<P></P>
<P align=left><B>p53 can repress wt but not mutant <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin in colon cancer cell lines.</B> The 
SW480 CRC cell line expresses a truncated APC that is deficient in its ability 
to promote <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin degradation (<A 
href="#B58">58</A>). Nevertheless, these cells contain phosphorylated 
<IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
that coprecipitates with the E3 ubiquitin ligase component <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-TrCP (<A 
href="#B29">29</A>), suggesting that the proteasomal degradation 
pathway responsible for <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin turnover is only partially attenuated 
in these cells. The endogenous p53 in SW480 cells has a mutation of 
Arg to His at position 273&nbsp;and another mutation of Pro to Ser at 
position 309&nbsp;(<A href="#B1">1</A>). Transfection of wt p53 into 
these cells led to a substantial drop in nuclear <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin levels (Fig. <A 
href="#F6">6</A>A and B). Computerized quantitation of the 
immunofluorescence images revealed about a twofold decrease in 
nuclear <IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
levels (Fig. <A href="#F6">6</A>C) and a fourfold reduction in <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin-mediated 
transactivation in these cells (Fig. <A href="#F6">6</A>D). <A 
name=F6><!-- FIG 6 --></A><BR clear=all>
<P>
<CENTER>
<TABLE border=1 cellPadding=0 cellSpacing=0 width="95%">
  <TBODY>
  <TR bgColor=#e1e1e1>
    <TD>
      <TABLE cellPadding=2 cellSpacing=2>
        <TBODY>
        <TR bgColor=#e1e1e1>
          <TD align=middle bgColor=#ffffff vAlign=top><A 
            href="/cgi/content/full/21/20/6768/F6"><IMG border=2 height=200 
            hspace=10 src="/content/vol21/issue20/images/small/mb2010174006.gif" 
            vspace=5 width=195></A><BR><STRONG>View larger version</STRONG> 
            (46K): <BR><NOBR><A href="/cgi/content/full/21/20/6768/F6">[in this 
            window]</A> <BR><A href="/cgi/content-nw/full/21/20/6768/F6" 
            onclick="startTarget('F6', 578, 640); this.href='/cgi/content-nw/full/21/20/6768/F6'" 
            onmouseover="window.status='View figure in a separate window'; return true" 
            target=F6>[in a new window]</A><BR>&nbsp; </NOBR></TD>
          <TD align=left vAlign=top><STRONG>FIG. 6. &nbsp;</STRONG> wt p53 
            down-regulates <IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-catenin in SW480 CRC cells. (A and 
            B) SW480 cells were transfected with HA-p53 (4&nbsp;Âµg) and 
            immunostained for HA (A) and <IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-catenin (<IMG align=bottom 
            alt="beta " src="/math/12pt/normal/beta.gif">-cat) (B) 20&nbsp;h 
            after transfection. The arrows point to the p53-transfected cells. 
            (C) Computerized quantitation of nuclear <IMG align=bottom 
            alt="beta " src="/math/12pt/normal/beta.gif">-catenin in control, 
            nontransfected cells and in p53-transfected cells. (D) 
            Transactivation in SW480 cells cotransfected with p53 and either 
            TOPFLASH or FOPFLASH reporter plasmid. Cells were harvested 
            20&nbsp;h after transfection and subjected to luciferase assay and 
            Western blot analysis for the transfected HA-p53. The position of 
            HA-p53 on the Western blot is indicated. Bar, 10&nbsp;Âµm. <BR 
            clear=left></TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER><!-- /FIG 6 -->
<P></P>The effect of p53 on mutant <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin was also examined in the HCT116 CRC 
cell line. These cells express mutant <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin with a deletion of serine 
45&nbsp;(<IMG align=bottom alt="Delta " src="/math/12pt/normal/Delta.gif">S45) 
and contain wt APC (<A href="#B57">57</A>) and wt p53 (<A 
href="#B19">19</A>). Treatment of HCT116 cells with DOX for 24&nbsp;h 
led to the nuclear accumulation of p53 (Fig. <A href="#F7">7</A>A [compare 
to Fig. <A href="#F7">7</A>C]), but no significant change in the <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin staining 
pattern or disruption of adherens junctions was observed in these 
cells (Fig. <A href="#F7">7</A>B [compare to Fig. <A 
href="#F7">7</A>D]). The analysis of the Triton X-100-soluble and 
-insoluble fractions from these cells also failed to reveal a 
significant change in <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin levels (Fig. <A href="#F7">7</A>E and 
F). Consistent with these observations, transfection of p53 into 
HCT116 cells also had no effect on the levels of the endogenous 
mutant <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin (data not shown). <A 
name=F7><!-- FIG 7 --></A><BR clear=all>
<P>
<CENTER>
<TABLE border=1 cellPadding=0 cellSpacing=0 width="95%">
  <TBODY>
  <TR bgColor=#e1e1e1>
    <TD>
      <TABLE cellPadding=2 cellSpacing=2>
        <TBODY>
        <TR bgColor=#e1e1e1>
          <TD align=middle bgColor=#ffffff vAlign=top><A 
            href="/cgi/content/full/21/20/6768/F7"><IMG border=2 height=135 
            hspace=10 src="/content/vol21/issue20/images/small/mb2010174007.gif" 
            vspace=5 width=200></A><BR><STRONG>View larger version</STRONG> 
            (84K): <BR><NOBR><A href="/cgi/content/full/21/20/6768/F7">[in this 
            window]</A> <BR><A href="/cgi/content-nw/full/21/20/6768/F7" 
            onclick="startTarget('F7', 590, 497); this.href='/cgi/content-nw/full/21/20/6768/F7'" 
            onmouseover="window.status='View figure in a separate window'; return true" 
            target=F7>[in a new window]</A><BR>&nbsp; </NOBR></TD>
          <TD align=left vAlign=top><STRONG>FIG. 7. &nbsp;</STRONG> p53 fails 
            to affect the mutant <IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-catenin <IMG align=bottom 
            alt="Delta " src="/math/12pt/normal/Delta.gif">S45 of HCT116 CRC 
            cells. (A to D) HCT116 cells were cultured on coverslips for 
            24&nbsp;h in either the presence (A and B) or the absence (C and D) 
            of 5&nbsp;Âµg of DOX per ml. After fixation, the cells were double 
            immunostained for p53 using a mixture of DO1 and 
            1801&nbsp;antibodies (A and C) and for <IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-catenin (<IMG align=bottom 
            alt="beta " src="/math/12pt/normal/beta.gif">-cat) (B and D) using a 
            polyclonal anti-<IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-catenin antibody. Bar, 10&nbsp;Âµm. 
            (E) HCT116 cells were treated with 5&nbsp;Âµg of DOX per ml for the 
            indicated times and fractionated into Triton X-100-soluble (lanes s) 
            and -insoluble (lanes i) fractions. The lysates were subjected to 
            Western blot analysis. The positions of <IMG align=bottom 
            alt="beta " src="/math/12pt/normal/beta.gif">-catenin, p53, and 
            vinculin (vin) (as a control) are indicated. (F) Quantitative 
            analysis of the intensities of the bands shown in panel E.&nbsp;au, 
            arbitrary units. <BR 
clear=left></TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER><!-- /FIG 7 -->
<P></P>The presence of deregulated mutant <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin in HCT116 cells results in 
constitutive <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin-mediated transcriptional activity 
(Fig. <A href="#F8">8</A>A, lane 7). In contrast to the case in SW480 
cells, excess wt p53 failed to inhibit the transcriptional activity 
of the endogenous mutant (<IMG align=bottom alt="Delta " 
src="/math/12pt/normal/Delta.gif">S45) <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin in HCT116 cells (Fig. <A 
href="#F8">8</A>A, lane 8&nbsp;[compare to lane 7]). However, p53 
repressed transactivation driven by excess transfected wt <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin (Fig. <A 
href="#F8">8</A>A, lanes 9&nbsp;and 10). This inhibition was 
accompanied by a reduction in the level of the transfected wt <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin (Fig. <A 
href="#F8">8</A>A, lanes 9&nbsp;and 10). In contrast, transfection of 
the more stable tumor-associated mutant <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin S33Y resulted in augmented 
transactivation that was resistant to wt p53 coexpression (Fig. <A 
href="#F8">8</A>A, lanes 11&nbsp;and 12). We also examined the 
ability of the endogenous wt p53 in HCT116 cells to affect <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin-mediated 
transactivation by inducing p53 expression with DOX. The results 
demonstrate that increasing endogenous p53 levels by this approach 
led to the inhibition of transactivation driven by the transfected wt 
<IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin (Fig. <A 
href="#F8">8</A>B, compare bars 5&nbsp;and 10&nbsp;to bar 4) but not 
by the mutant endogenous <IMG align=bottom alt="Delta " 
src="/math/12pt/normal/Delta.gif">S45 <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin or the transfected mutant 
<IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin S33Y, 
which were resistant to elevated p53 (Fig, 8B, compare bars 4&nbsp;to 
10&nbsp;and 6&nbsp;to 12). These results suggest that the cellular 
machinery necessary for the inhibitory effect of p53 on <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin is intact in 
HCT116 cells and that the inability of wt p53 to down-regulate the 
endogenous <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin (<IMG align=bottom alt="Delta " 
src="/math/12pt/normal/Delta.gif">S45) or the transfected S33Y is due to the 
N-terminal mutations in the serine motifs that regulate <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
degradation. <A name=F8><!-- FIG 8 --></A><BR clear=all>
<P>
<CENTER>
<TABLE border=1 cellPadding=0 cellSpacing=0 width="95%">
  <TBODY>
  <TR bgColor=#e1e1e1>
    <TD>
      <TABLE cellPadding=2 cellSpacing=2>
        <TBODY>
        <TR bgColor=#e1e1e1>
          <TD align=middle bgColor=#ffffff vAlign=top><A 
            href="/cgi/content/full/21/20/6768/F8"><IMG border=2 height=200 
            hspace=10 src="/content/vol21/issue20/images/small/mb2010174008.gif" 
            vspace=5 width=100></A><BR><STRONG>View larger version</STRONG> 
            (25K): <BR><NOBR><A href="/cgi/content/full/21/20/6768/F8">[in this 
            window]</A> <BR><A href="/cgi/content-nw/full/21/20/6768/F8" 
            onclick="startTarget('F8', 369, 640); this.href='/cgi/content-nw/full/21/20/6768/F8'" 
            onmouseover="window.status='View figure in a separate window'; return true" 
            target=F8>[in a new window]</A><BR>&nbsp; </NOBR></TD>
          <TD align=left vAlign=top><STRONG>FIG. 8. &nbsp;</STRONG> p53 does 
            not inhibit transactivation by the <IMG align=bottom alt="Delta " 
            src="/math/12pt/normal/Delta.gif">S45 <IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-catenin of HCT116 cells and of 
            transfected S33Y but inhibits the activity of wt <IMG align=bottom 
            alt="beta " src="/math/12pt/normal/beta.gif">-catenin in these 
            cells. (A) HCT116 cells were transfected with FOPFLASH (lanes 
            1&nbsp;to 5) or TOPFLASH (lanes 7&nbsp;to 12), together with p53 
            (lanes 2,&nbsp;4,&nbsp;6,&nbsp;8,&nbsp;10,&nbsp;and 12), HA-<IMG 
            align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
            (lanes 3,&nbsp;4,&nbsp;9,&nbsp;and 10), or p53 and HA-S33Y <IMG 
            align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
            (lanes 5,&nbsp;6,&nbsp;11,&nbsp;and 12). Luciferase activity was 
            determined 20&nbsp;h after transfection, and Western blot analyses 
            of the cell lysates for the expression of <IMG align=bottom 
            alt="beta " src="/math/12pt/normal/beta.gif">-catenin (<IMG 
            align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-cat) (wt) 
            and the mutant (S33Y) and for p53 were performed. (B) HCT116 cells 
            were transfected with wt and S33Y <IMG align=bottom alt="beta " 
            src="/math/12pt/normal/beta.gif">-catenin and either treated with 
            DOX (to elevate p53 levels) as described for Fig. <A 
            href="#F7">7</A> (bars 7&nbsp;to 12) or left untreated (bars 
            1&nbsp;to 6). Transactivation driven by the FOPFLASH and TOPFLASH 
            reporter plasmids was determined. The standard error is shown. <BR 
            clear=left></TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER><!-- /FIG 8 -->
<P></P>Taken together, the results imply that mutations within the GSK3<IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif"> phosphorylation 
domain of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin that render it more 
resistant to proteasomal degradation also make <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin more resistant 
to down-regulation by activated p53. Importantly, such <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin mutations are 
prevalent in a variety of human cancers. 
<P></P><BR clear=all><A name=Discussion><!-- null --></A>
<TABLE bgColor=#e1e1e1 cellPadding=0 cellSpacing=0 width="100%">
  <TBODY>
  <TR>
    <TD align=left bgColor=#ffffff vAlign=center width="5%">&nbsp;<IMG alt="" 
      height=21 hspace=5 src="/icons/toc/rarrow.gif" width=10></TD>
    <TH align=left vAlign=center width="95%"><FONT 
      size=+2>&nbsp;&nbsp;DISCUSSION</FONT></TH></TR></TBODY></TABLE>
<TABLE align=right border=1 cellPadding=5 NOWRAP><R>
  <TBODY>
  <TR>
    <TH align=left><FONT size=-1><A href="#Top"><IMG border=0 height=9 
      hspace=5 src="/icons/toc/uarrow.gif" width=11> Top</A> <BR><A 
      href="#Abstract"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/uarrow.gif" width=11> Abstract</A> <BR><A 
      href="#Introduction"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/uarrow.gif" width=11> Introduction</A> <BR><A 
      href="#MaterialsMethods"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/uarrow.gif" width=11> Materials and Methods</A> <BR><A 
      href="#Results"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/uarrow.gif" width=11> Results</A> <BR><IMG border=0 
      height=9 hspace=5 src="/icons/toc/dot.gif" width=11><FONT color=#464c53> 
      Discussion</FONT> <BR><A href="#References"><IMG border=0 height=9 
      hspace=5 src="/icons/toc/darrow.gif" width=11> References</A> 
  </FONT></TH></TR></TBODY></TABLE>
<P>This study demonstrated that high levels of functional p53 could 
down-regulate the amount and transcriptional activity of <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin. This effect 
was eliminated by blocking the activities of components that regulate 
the turnover of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin, such as GSK3<IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">, a dominant-negative 
form of <IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-TrCP, 
and the proteasomal system. p53 therefore most probably exerted its 
effect by accelerating the degradation of <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin by the proteasome. While 
p53 could down-regulate wt <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin in the presence of wt or even 
mutant APC, it failed to affect mutants of <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin that are resistant 
to the APC-GSK3<IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-axin-mediated degradation. It is unlikely 
that the basal low levels of p53 in nonstressed cells are 
sufficient to cause <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin down-regulation. Rather, it is 
conceivable that this inhibitory effect is exerted only by high 
levels of activated p53, as seen in cells exposed to extensive 
genotoxic stress (Fig. <A href="#F2">2</A>). Constitutive activity of 
<IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin can 
exert both proliferative and antiapoptotic effects (<A 
href="#B62">62</A>). Hence, the down-regulation of <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin by activated p53 is likely 
to contribute to the antiproliferative effects of p53 and possibly 
also facilitates p53-mediated apoptosis. While in our experiments p53 
activation was attained by treatment of cultured cells with 
DNA-damaging agents, it is conceivable that a similar situation may 
pertain also in emerging colorectal tumors with multiple genomic 
aberrations, which is typical of late stages in colorectal 
carcinogenesis. </P>
<P>The exact molecular mechanism responsible for the down-regulation of <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin by p53 
remains to be elucidated. So far, we have been unable to demonstrate 
a direct protein-protein interaction between p53 and <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin (data not 
shown), suggesting that additional proteins are likely to play a role 
in mediating <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin down-regulation. p53 is a 
transcription factor, which is capable of direct sequence-specific 
transcription activation and indirect, albeit target gene selective, 
transcriptional repression. We have shown that p53 mutants deficient 
in transcriptional activity, owing either to deletion of the 
transactivation domain (p53<IMG align=bottom alt="Delta " 
src="/math/12pt/normal/Delta.gif">13-52) or to a more global conformational 
change affecting both the DNA binding and the transactivation domains 
(p53R175H), failed to reduce <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin levels. These findings support 
the view that the down-modulation of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin depends on the transcriptional 
activities of p53. For example, the decrease in <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin might be 
mediated by the action of the products of one or several p53 target 
genes whose expression is induced in cells exposed to high levels of 
activated p53. One interesting possibility is suggested by studies 
showing that APC mRNA is induced by excess p53 in several cell types 
(<A href="#B59">59</A>). Such induction of APC expression by p53 may 
contribute to enhanced <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin degradation in cells carrying 
a functional APC gene and may account for part of the observed 
reduction in <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin protein following p53 elevation. This 
observation cannot, however, explain the ability of p53 to reduce 
<IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
expression in SW480 CRC cells, which harbor a mutant APC gene 
and are devoid of functional APC protein. </P>
<P>Another potential contributor to the inhibitory effect of p53 on <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin is the 
Dickkopf protein, whose gene has recently been reported to be subject 
to transcriptional activation by p53 (<A href="#B85">85</A>). 
Dickkopf-1 blocks low-density lipoprotein (LDL) receptor-related 
protein 6-mediated Wnt/<IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin signaling by directly interacting 
with LDL receptor-related protein 6&nbsp;(<A href="#B49">49</A>). In 
addition to transactivation, transcriptional repression by p53 may 
also play a role in suppressing <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin. One potential mediator of such an 
effect may be presenilin 1,&nbsp;whose expression is repressed by p53 
(<A href="#B69">69</A>). Since presenilin 1&nbsp;can stabilize <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin (<A 
href="#B92">92</A>), its down-regulation by p53 might lead to 
destabilization of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin. It is conceivable that 
additional p53-regulated genes may also play a role in the 
down-regulation of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin, and p53 might turn on a coordinated 
transcriptional program designed to inhibit <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin-mediated 
signaling. </P>
<P>While this paper was under revision, two studies were published suggesting 
that Siah-1, a transcriptional target of p53, can down-regulate <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin. Liu et al. 
(<A href="#B47">47</A>) and Matsuzawa and Reed (<A 
href="#B51">51</A>) reported that a p53-inducible gene product(Siah-1) can 
mediate the down-regulation of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin by a novel degradation 
pathway mediated by SIP, Ebi, and the carboxy terminus of APC. 
This novel pathway may provide an additional means by which p53 
can inhibit the accumulation of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin, especially of the oncogenic 
<IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
mutants with mutations in the GSK phosphorylation sites, since this 
pathway operates independently of GSK3<IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif"> (<A href="#B47">47</A>). It is of 
note that whereas overexpression of Siah-1 in SW480 cells was unable 
to inhibit <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin signaling (<A href="#B47">47</A>), 
transfection of p53 into these cells did cause a marked reduction in 
the level of nuclear <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin and LEF-dependent transcription (Fig. 
<A href="#F6">6</A>). Taken together, these observations imply that 
p53 can block <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin signaling through multiple 
downstream effectors, with Siah-1 being just one of those. Minimally, 
the data argue that there are at least two major alternative pathways 
for p53-induced suppression of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin: a canonical cascade involving 
components of the Wnt pathway and a second mechanism involving 
Siah-1, SIP, and Ebi. Both pathways are probably turned on 
simultaneously when p53 levels become sufficiently elevated, and they 
may synergize to achieve a more effective response. This could be 
particularly important when the target is an abundant protein such as 
<IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin. 
The relative contribution of each of the two pathways to the 
elimination of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin signaling probably varies with cell 
type and cell context and may be modulated by additional genetic 
alterations that occur in the course of tumorigenesis. Furthermore, 
the existence of multiple parallel pathways for down-regulating <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin by 
activated p53 may provide a fail-safe mechanism in case one of 
the components along either of the pathways becomes 
inactivated. </P>
<P>Alternatively, p53 and <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin may compete for a common interacting 
molecule required for <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin stabilization. A possible 
candidate is the p300 (also called CBP) transcriptional coactivator, 
since both p53 and <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin can bind to p300 (<A href="#B6">6</A>, 
<A href="#B33">33</A>, <A href="#B79">79</A>) and a recent study has 
shown that p53 and <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin compete for p300 binding 
(<A href="#B53">53</A>). A similar competition for p300 binding between 
p53 and NF-<IMG align=bottom alt="kappa " 
src="/math/12pt/normal/kappa.gif">B, resulting in the inhibition of the 
transcriptional activity of each of these proteins by an excess of 
the other, has been described (<A href="#B86">86</A>). Our 
preliminary results indicate that overexpression of p300 can protect 
wt <IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin from 
down-regulation by p53 (data not shown). It is thus tempting to 
speculate that when p300 is present in limited amounts, increased p53 
levels can displace the endogenous <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin from its complex with p300 
and render it more susceptible to ubiquitination and 
degradation. </P>
<P>A simple explanation that needs to be ruled out is that the reduction in <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin protein is 
merely a consequence of p53-mediated apoptosis. Such a possibility 
may rely on previous observations that <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin is subject to cleavage by caspases, 
mainly caspases 3,&nbsp;6,&nbsp;and 8,&nbsp;in cells undergoing 
apoptosis (<A href="#B11">11</A>, <A href="#B81">81</A>). We believe 
that this is an unlikely explanation for the effects of p53 on 
<IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
for several reasons. First, no morphological changes suggestive of 
apoptosis were noted in any of the cell types used in this study when 
the cells were harvested for biochemical and immunohistochemical 
analysis (Fig. <A href="#F1">1</A>, <A href="#F6">6</A>, and <A href="#F7">7</A> 
and data not shown). In addition, using the same antibody which was 
employed to demonstrate caspase-mediated <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin cleavage (<A 
href="#B11">11</A>, <A href="#B81">81</A>), we did not detect cleaved 
forms of <IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
in extracts of cells exposed to high p53 activity (Fig. <A 
href="#F1">1</A>A, C, and E and 7E and data not shown). Hence, we 
suggest that the effect of p53 on <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin most probably is exerted 
through the pathway responsible for the normal proteasomal 
degradation of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin. </P>
<P>A previous study has shown that excess deregulated <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin can lead to the induction 
of active p53 (<A href="#B15">15</A>) and that this is also achieved 
through changes in the rate of proteasomal degradation of the 
affected protein (p53). In the present study, we demonstrate a 
reciprocal relationship between p53 and <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin in the same cell system by 
comparing the levels of the two proteins under conditions in which 
one protein was in excess over the other (Fig. <A href="#F3">3</A>D). 
It is clear from these results that increasing levels of <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin augment the 
levels of p53 when a constant amount of p53 is cotransduced into the 
same cells. On the other hand, when high levels of <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin are transfected, elevation 
of p53 results in a specific, dose-dependent down-regulation of <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
expression (Fig. <A href="#F3">3</A>D). Taken together, these studies 
delineate an autoregulatory loop in which excess <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin induces p53 activation, 
which in turn leads to down-regulation of <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin levels and activity. 
This control loop might serve as an effective means for curbing 
the potential oncogenic effects of deregulated <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin. Its disruption 
may unleash the oncogenic activity of <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin, thereby contributing to 
tumor progression. The disruption of such autoregulation may occur 
through mutations in the p53 gene that will render it unable to 
repress <IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
activity or by inactivation of the tumor suppressor ARF, which 
stabilizes p53 (<A href="#B72">72</A>). It is noteworthy that the 
ability to repress <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin is lost in the p53R175H 
mutant, which is frequently seen in human CRC where <IMG align=bottom 
alt="beta " src="/math/12pt/normal/beta.gif">-catenin is deregulated 
through the loss of functional APC (<A href="#B39">39</A>, <A 
href="#B60">60</A>). This loop may also be disrupted by mutations in 
<IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
that render it resistant to the inhibitory effect of p53, as is 
the case with the S33Y <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin mutant. In this regard, it is of 
interest that while p53 mutations predominate in the major class 
of CRC (involving <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin deregulation through APC gene 
inactivation), they are significantly less frequent in CRC carrying 
direct stabilizing mutations within <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin itself (<A href="#B17">17</A>, <A 
href="#B44">44</A>, <A href="#B52">52</A>, <A href="#B75">75</A>, <A 
href="#B77">77</A>). Moreover, in a recent study employing N-myc 
transgenic mice, the majority of liver tumors arising on a 
p53+/<IMG align=bottom alt=- src="/math/12pt/normal/scr/minus.gif"> 
background displayed either a <IMG align=bottom alt="beta " 
src="/math/12pt/normal/beta.gif">-catenin mutation or a loss of the 
remaining p53 allele (<A href="#B67">67</A>). This further suggests that 
these two mutational events often tend to be mutually exclusive 
during tumorigenesis. Our findings offer an appealing explanation 
for these observations by predicting that early mutations in <IMG 
align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
will render it refractory to down-regulation by p53, thereby 
significantly reducing the pressure for subsequent mutational 
inactivation of p53. Conversely, the predominance of p53 mutations in 
the major class of CRC, which are associated with APC inactivation, 
suggests that the ability of wt p53 to restrain the deregulated wt 
<IMG align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
is a key component of its tumor suppressor function and a major 
cause for the elimination of p53 function in such tumors. 
</P></TXT><!-- Stray figures and tables --><!-- Appendices --><!-- Acknowledgments --><A 
name=ack><!-- comment for mosaic --></A><BR clear=all>
<TABLE bgColor=#e1e1e1 cellPadding=0 cellSpacing=0 width="100%">
  <TBODY>
  <TR>
    <TD align=left bgColor=#ffffff vAlign=center width="5%">&nbsp;<IMG alt="" 
      height=21 hspace=5 src="/icons/toc/rarrow.gif" width=10></TD>
    <TH align=left vAlign=center width="95%"><FONT 
      size=+2>&nbsp;&nbsp;ACKNOWLEDGMENTS</FONT></TH></TR></TBODY></TABLE>
<P>This study was supported by grants from the German-Israeli Foundation for 
Scientific Research and Development, the Cooperation Program in 
Cancer Research between the German Cancer Research Center (DKFZ) and 
the Israeli Ministry of Science and Arts (IMOSA), CaP CURE, The 
Israel Science Foundation, The Crown Endowment Fund for Immunological 
Research, The M.&nbsp;D.&nbsp;Moross Institute for Cancer Research, 
NIH (grant RO1 CA-40099), and the German-Israel Project Cooperation 
(DIP). B.G. holds the E.&nbsp;Neter Chair of Cell and Tumor Biology, 
and A.B.-Z. holds the Lunenfeld-Kunin Chair in Genetics and Cell 
Biology. </P>
<P>We thank G.&nbsp;Del Sal and J.&nbsp;Zhurinsky for illuminating 
discussions. </P><!-- Notes --><!-- Footnotes --><A name=foo><!-- comment for mosaic --></A><BR clear=all>
<TABLE bgColor=#e1e1e1 cellPadding=0 cellSpacing=0 width="100%">
  <TBODY>
  <TR>
    <TD align=left bgColor=#ffffff vAlign=center width="5%">&nbsp;<IMG alt="" 
      height=21 hspace=5 src="/icons/toc/rarrow.gif" width=10></TD>
    <TH align=left vAlign=center width="95%"><FONT 
      size=+2>&nbsp;&nbsp;FOOTNOTES</FONT></TH></TR></TBODY></TABLE>
<P><A name=FN150>*</A> Corresponding author. Mailing address: 
Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot 
76100,&nbsp;Israel. Phone: (972) 8-934&nbsp;2422.&nbsp;Fax: (972) 
8-946&nbsp;5261.&nbsp;E-mail: <A 
href="mailto:avri.ben-zeev@weizmann.ac.il">avri.ben-zeev@weizmann.ac.il</A>. 
<P><!-- Abbreviations --><!-- Bibliography --><BR clear=all><A name=References><!-- null --></A>
<TABLE bgColor=#e1e1e1 cellPadding=0 cellSpacing=0 width="100%">
  <TBODY>
  <TR>
    <TD align=left bgColor=#ffffff vAlign=center width="5%">&nbsp;<IMG alt="" 
      height=21 hspace=5 src="/icons/toc/rarrow.gif" width=10></TD>
    <TH align=left vAlign=center width="95%"><FONT 
      size=+2>&nbsp;&nbsp;REFERENCES</FONT></TH></TR></TBODY></TABLE>
<TABLE align=right border=1 cellPadding=5 NOWRAP><R>
  <TBODY>
  <TR>
    <TH align=left><FONT size=-1><A href="#Top"><IMG border=0 height=9 
      hspace=5 src="/icons/toc/uarrow.gif" width=11> Top</A> <BR><A 
      href="#Abstract"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/uarrow.gif" width=11> Abstract</A> <BR><A 
      href="#Introduction"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/uarrow.gif" width=11> Introduction</A> <BR><A 
      href="#MaterialsMethods"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/uarrow.gif" width=11> Materials and Methods</A> <BR><A 
      href="#Results"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/uarrow.gif" width=11> Results</A> <BR><A 
      href="#Discussion"><IMG border=0 height=9 hspace=5 
      src="/icons/toc/uarrow.gif" width=11> Discussion</A> <BR><IMG border=0 
      height=9 hspace=5 src="/icons/toc/dot.gif" width=11><FONT color=#464c53> 
      References</FONT> </FONT></TH></TR></TBODY></TABLE><BR clear=all>
<TABLE border=0>
  <TBODY>
  <TR>
    <TD vAlign=top><A name=B1>1.</A> 
    <TD vAlign=top><STRONG>Abarzua, P., J. E. LoSardo, M. L. Gubler, and A. 
      Neri.</STRONG> 1995. Microinjection of monoclonal antibody PAb421 into 
      human SW480 colorectal carcinoma cells restores the transcription 
      activation function to mutant p53. Cancer Res. <B>55</B><B>:</B>3490-3494<!-- HIGHWIRE ID="21:20:6768:1" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=canres&amp;resid=55/16/3490">[Abstract]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B2>2.</A> 
    <TD vAlign=top><STRONG>Adams, C., and W. Nelson.</STRONG> 1998. 
      Cytomechanics of cadherin-mediated cell-cell adhesion. Curr. Opin. Cell 
      Biol. <B>10</B><B>:</B>572-577<!-- HIGHWIRE ID="21:20:6768:2" --><A 
      href="/cgi/external_ref?access_num=10.1016/S0955-0674(98)80031-8&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=9818166&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B3>3.</A> 
    <TD vAlign=top><STRONG>Albrechtsen, N., I. Dornreiter, F. Grosse, E. Kim, 
      L. Wiesmuller, and W. Deppert.</STRONG> 1999. Maintenance of genomic 
      integrity by p53: complementary roles for activated and non-activated p53. 
      Oncogene <B>18</B><B>:</B>7706-7717<!-- HIGHWIRE ID="21:20:6768:3" --><A 
      href="/cgi/external_ref?access_num=10.1038/sj.onc.1202952&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=10618711&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B4>4.</A> 
    <TD vAlign=top><STRONG>Ashcroft, M., Y. Taya, and K. H. Vousden.</STRONG> 
      2000. Stress signals utilize multiple pathways to stabilize p53. Mol. 
      Cell. Biol. 
      <B>20</B><B>:</B>3224-3233<!-- HIGHWIRE ID="21:20:6768:4" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=mcb&amp;resid=20/9/3224"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B5>5.</A> 
    <TD vAlign=top><STRONG>Ashcroft, M., and K. H. Vousden.</STRONG> 1999. 
      Regulation of p53 stability. Oncogene <B>18</B><B>:</B>7637-7643<!-- HIGHWIRE ID="21:20:6768:5" --><A 
      href="/cgi/external_ref?access_num=10.1038/sj.onc.1203012&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=10618703&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B6>6.</A> 
    <TD vAlign=top><STRONG>Avantaggiati, M. L., V. Ogryzko, K. Gardner, A. 
      Giordano, A. S. Levine, and K. Kelly.</STRONG> 1997. Recruitment of 
      p300/CBP in p53-dependent signal pathways. Cell <B>89</B><B>:</B>1175-1184<!-- HIGHWIRE ID="21:20:6768:6" --><A 
      href="/cgi/external_ref?access_num=9215639&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B7>7.</A> 
    <TD vAlign=top><STRONG>Baker, S. J., E. R. Fearon, J. M. Nigro, S. R. 
      Hamilton, A. C. Preisinger, J. M. Jessup, P. vanTuinen, D. H. Ledbetter, 
      D. F. Barker, Y. Nakamura, R. White, and B. Vogelstein.</STRONG> 1989. 
      Chromosome 17&nbsp;deletions and p53 gene mutations in colorectal 
      carcinomas. Science <B>244</B><B>:</B>217-221<!-- HIGHWIRE ID="21:20:6768:7" --><A 
      href="/cgi/external_ref?access_num=2649981&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B8>8.</A> 
    <TD vAlign=top><STRONG>Banks, L., G. Matlashewski, and L. 
      Crawford.</STRONG> 1986. Isolation of human-p53-specific monoclonal 
      antibodies and their use in the studies of human p53 expression. Eur. 
      J.&nbsp;Biochem. <B>159</B><B>:</B>529-534<!-- HIGHWIRE ID="21:20:6768:8" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=ejbiochem&amp;resid=159/3/529">[Abstract]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B9>9.</A> 
    <TD vAlign=top><STRONG>Behrens, J., J. von Kries, M. Kuhl, L. Bruhn, D. 
      Wedlich, R. Grosschedl, and W. Birchmeier.</STRONG> 1996. Functional 
      interaction of beta-catenin with the transcription factor LEF-1. Nature 
      <B>382</B><B>:</B>638-642<!-- HIGHWIRE ID="21:20:6768:9" --><A 
      href="/cgi/external_ref?access_num=8757136&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B10>10.</A> 
    <TD vAlign=top><STRONG>Ben-Ze'ev, A., and B. Geiger.</STRONG> 1998. 
      Differential molecular interactions of beta-catenin and plakoglobin in 
      adhesion, signaling and cancer. Curr. Opin. Cell Biol. 
      <B>10</B><B>:</B>629-639<!-- HIGHWIRE ID="21:20:6768:10" --><A 
      href="/cgi/external_ref?access_num=10.1016/S0955-0674(98)80039-2&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=9818174&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B11>11.</A> 
    <TD vAlign=top><STRONG>Brancolini, C., D. Lazarevic, J. Rodriguez, and C. 
      Schneider.</STRONG> 1997. Dismantling cell-cell contacts during apoptosis 
      is coupled to a caspase-dependent proteolytic cleavage of beta-catenin. J. 
      Cell. Biol. 
      <B>139</B><B>:</B>759-771<!-- HIGHWIRE ID="21:20:6768:11" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=jcb&amp;resid=139/3/759"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B12>12.</A> 
    <TD vAlign=top><STRONG>Burns, T. F., and W. S. El-Deiry.</STRONG> 1999. 
      The p53 pathway and apoptosis. J. Cell. Physiol. <B>181</B><B>:</B>231-239<!-- HIGHWIRE ID="21:20:6768:12" --><A 
      href="/cgi/external_ref?access_num=10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.3.CO;2-C&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=10497302&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B13>13.</A> 
    <TD vAlign=top><STRONG>Chan, E., U. Gat, J. McNiff, and E. Fuchs.</STRONG> 
      1999. A common human skin tumour is caused by activating mutations in 
      beta-catenin. Nat. Genet. <B>21</B><B>:</B>410-413<!-- HIGHWIRE ID="21:20:6768:13" --><A 
      href="/cgi/external_ref?access_num=10.1038/7747&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=10192393&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B14>14.</A> 
    <TD vAlign=top><STRONG>Crawford, H., B. Fingleton, L. Rudolph-Owen, K. 
      Goss, B. Rubinfeld, P. Polakis, and L. Matrisian.</STRONG> 1999. The 
      metalloproteinase matrilysin is a target of beta-catenin transactivation 
      in intestinal tumors. Oncogene <B>18</B><B>:</B>2883-2891<!-- HIGHWIRE ID="21:20:6768:14" --><A 
      href="/cgi/external_ref?access_num=10.1038/sj.onc.1202627&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=10362259&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B15>15.</A> 
    <TD vAlign=top><STRONG>Damalas, A., A. Ben-Ze'ev, I. Simcha, M. Shtutman, 
      J. Leal, J. Zhurinsky, B. Geiger, and M. Oren.</STRONG> 1999. Excess <IMG 
      align=bottom alt="beta " src="/math/12pt/normal/beta.gif">-catenin 
      promotes accumulation of transcriptionally active p53. EMBO J. 
      <B>18</B><B>:</B>3054-3063<!-- HIGHWIRE ID="21:20:6768:15" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=emboj&amp;resid=18/11/3054"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B16>16.</A> 
    <TD vAlign=top><STRONG>de La Coste, A., B. Romagnolo, P. Billuart, C. A. 
      Renard, M. A. Buendia, O. Soubrane, M. Fabre, J. Chelly, C. Beldjord, A. 
      Kahn, and C. Perret.</STRONG> 1998. Somatic mutations of the beta-catenin 
      gene are frequent in mouse and human hepatocellular carcinomas. Proc. 
      Natl. Acad. Sci. USA <B>95</B><B>:</B>8847-8851<!-- HIGHWIRE ID="21:20:6768:16" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=pnas&amp;resid=95/15/8847"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B17>17.</A> 
    <TD vAlign=top><STRONG>Delattre, O., S. Olschwang, D. J. Law, T. Melot, Y. 
      Remvikos, R. J. Salmon, X. Sastre, P. Validire, A. P. Feinberg, and G. 
      Thomas.</STRONG> 1989. Multiple genetic alterations in distal and proximal 
      colorectal cancer. Lancet <B>2</B><B>:</B>353-356<!-- HIGHWIRE ID="21:20:6768:17" --><A 
      href="/cgi/external_ref?access_num=2569552&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B18>18.</A> 
    <TD vAlign=top><STRONG>el-Deiry, W. S.</STRONG> 1998. Regulation of p53 
      downstream genes. Semin. Cancer Biol. <B>8</B><B>:</B>345-357<!-- HIGHWIRE ID="21:20:6768:18" --><A 
      href="/cgi/external_ref?access_num=10.1006/scbi.1998.0097&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=10101800&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B19>19.</A> 
    <TD vAlign=top><STRONG>el-Deiry, W. S., J. W. Harper, P. M. O'Connor, V. 
      E. Velculescu, C. E. Canman, J. Jackman, J. A. Pietenpol, M. Burrell, D. 
      E. Hill, Y. Wang, et al.</STRONG> 1994. WAF1/CIP1 is induced in 
      p53-mediated G1 arrest and apoptosis. Cancer Res. 
      <B>54</B><B>:</B>1169-1174<!-- HIGHWIRE ID="21:20:6768:19" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=canres&amp;resid=54/5/1169">[Abstract]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B20>20.</A> 
    <TD vAlign=top><STRONG>Eliyahu, D., D. Michalovitz, S. Eliyahu, O. 
      Pinhasi-Kimhi, and M. Oren.</STRONG> 1989. Wild-type p53 can inhibit 
      oncogene-mediated focus formation. Proc. Natl. Acad. Sci. USA 
      <B>86</B><B>:</B>8763-8767<!-- HIGHWIRE ID="21:20:6768:20" --><A 
      href="/cgi/external_ref?access_num=2530586&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B21>21.</A> 
    <TD vAlign=top><STRONG>Fuchs, S. Y., A. Chen, Y. Xiong, Z. Q. Pan, and Z. 
      Ronai.</STRONG> 1999. HOS, a human homolog of Slimb, forms an SCF complex 
      with Skp1 and Cullin1 and targets the phosphorylation-dependent 
      degradation of IkappaB and beta-catenin. Oncogene 
      <B>18</B><B>:</B>2039-2046<!-- HIGHWIRE ID="21:20:6768:21" --><A 
      href="/cgi/external_ref?access_num=10.1038/sj.onc.1202760&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=10321728&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B22>22.</A> 
    <TD vAlign=top><STRONG>Fukuchi, T., M. Sakamoto, H. Tsuda, K. Maruyama, S. 
      Nozawa, and S. Hirohashi.</STRONG> 1998. Beta-catenin mutation in 
      carcinoma of the uterine endometrium. Cancer Res. 
      <B>58</B><B>:</B>3526-3528<!-- HIGHWIRE ID="21:20:6768:22" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=canres&amp;resid=58/16/3526">[Abstract]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B23>23.</A> 
    <TD vAlign=top><STRONG>Gamallo, C., J. Palacios, G. Moreno, J. Calvo de 
      Mora, A. Suarez, and A. Armas.</STRONG> 1999. Beta-catenin expression 
      pattern in stage I and II ovarian carcinomas: relationship with 
      beta-catenin gene mutations, clinicopathological features, and clinical 
      outcome. Am. J.&nbsp;Pathol. <B>155</B><B>:</B>527-536<!-- HIGHWIRE ID="21:20:6768:23" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=amjpathol&amp;resid=155/2/527"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B24>24.</A> 
    <TD vAlign=top><STRONG>Garcia-Rostan, G., G. Tallini, A. Herrero, T. G. 
      D'Aquila, M. L. Carcangiu, and D. L. Rimm.</STRONG> 1999. Frequent 
      mutation and nuclear localization of beta-catenin in anaplastic thyroid 
      carcinoma. Cancer Res. <B>59</B><B>:</B>1811-1815<!-- HIGHWIRE ID="21:20:6768:24" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=canres&amp;resid=59/8/1811"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B25>25.</A> 
    <TD vAlign=top><STRONG>Gat, U., R. DasGupta, L. Degenstein, and E. 
      Fuchs.</STRONG> 1998. De novo hair follicle morphogenesis and hair tumors 
      in mice expressing a truncated beta-catenin in skin. Cell 
      <B>95</B><B>:</B>605-614<!-- HIGHWIRE ID="21:20:6768:25" --><A 
      href="/cgi/external_ref?access_num=9845363&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B26>26.</A> 
    <TD vAlign=top><STRONG>Gradl, D., M. Kuhl, and D. Wedlich.</STRONG> 1999. 
      The Wnt/Wg signal transducer beta-catenin controls fibronectin expression. 
      Mol. Cell. Biol. <B>19</B><B>:</B>5576-5587<!-- HIGHWIRE ID="21:20:6768:26" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=mcb&amp;resid=19/8/5576"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B27>27.</A> 
    <TD vAlign=top><STRONG>Harada, N., Y. Tamai, T. Ishikawa, B. Sauer, K. 
      Takaku, M. Oshima, and M. M. Taketo.</STRONG> 1999. Intestinal polyposis 
      in mice with a dominant stable mutation of the beta-catenin gene. EMBO J. 
      <B>18</B><B>:</B>5931-5942<!-- HIGHWIRE ID="21:20:6768:27" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=emboj&amp;resid=18/21/5931"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B28>28.</A> 
    <TD vAlign=top><STRONG>Harlow, E. D., L. V. Crawford, D. C. Pim, and N. M. 
      Williamson.</STRONG> 1981. Monoclonal antibodies specific for simian virus 
      40&nbsp;tumor antigens. J. Virol. <B>39</B><B>:</B>861-869<!-- HIGHWIRE ID="21:20:6768:28" --><A 
      href="/cgi/external_ref?access_num=6169844&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B29>29.</A> 
    <TD vAlign=top><STRONG>Hart, M., J. Concordet, I. Lassot, I. Albert, R. 
      del los Santos, H. Durand, C. Perret, B. Rubinfeld, F. Margottin, R. 
      Benarous, and P. Polakis.</STRONG> 1999. The F-box protein beta-TrCP 
      associates with phosphorylated beta-catenin and regulates its activity in 
      the cell. Curr. Biol. <B>9</B><B>:</B>207-210<!-- HIGHWIRE ID="21:20:6768:29" --><A 
      href="/cgi/external_ref?access_num=10.1016/S0960-9822(99)80091-8&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=10074433&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B30>30.</A> 
    <TD vAlign=top><STRONG>Haupt, Y., Y. Barak, and M. Oren.</STRONG> 1996. 
      Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 
      <B>15</B><B>:</B>1596-1606<!-- HIGHWIRE ID="21:20:6768:30" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=emboj&amp;resid=15/7/1596">[Abstract]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B31>31.</A> 
    <TD vAlign=top><STRONG>He, T., T. Chan, B. Vogelstein, and K. 
      Kinzler.</STRONG> 1999. PPARdelta is an APC-regulated target of 
      nonsteroidal anti-inflammatory drugs. Cell <B>99</B><B>:</B>335-345<!-- HIGHWIRE ID="21:20:6768:31" --><A 
      href="/cgi/external_ref?access_num=10555149&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B32>32.</A> 
    <TD vAlign=top><STRONG>He, T., A. Sparks, C. Rago, H. Hermeking, L. Zawel, 
      L. da Costa, P. Morin, B. Vogelstein, and K. Kinzler.</STRONG> 1998. 
      Identification of c-MYC as a target of the APC pathway. Science 
      <B>281</B><B>:</B>1509-1512<!-- HIGHWIRE ID="21:20:6768:32" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=sci&amp;resid=281/5382/1509"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B33>33.</A> 
    <TD vAlign=top><STRONG>Hecht, A., K. Vleminckx, M. Stemmler, F. van Roy, 
      and R. Kemler.</STRONG> 2000. The p300/CBP acetyltransferases function as 
      transcriptional coactivators of beta-catenin in vertebrates. EMBO J. 
      <B>19</B><B>:</B>1839-1850<!-- HIGHWIRE ID="21:20:6768:33" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=emboj&amp;resid=19/8/1839"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B34>34.</A> 
    <TD vAlign=top><STRONG>Huber, O., R. Korn, J. McLaughlin, M. Ohsugi, B. 
      Herrmann, and R. Kemler.</STRONG> 1996. Nuclear localization of 
      beta-catenin by interaction with transcription factor LEF-1. Mech. Dev. 
      <B>59</B><B>:</B>3-10<!-- HIGHWIRE ID="21:20:6768:34" --><A 
      href="/cgi/external_ref?access_num=10.1016/0925-4773(96)00597-7&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=8892228&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B35>35.</A> 
    <TD vAlign=top><STRONG>Janus, F., N. Albrechtsen, I. Dornreiter, L. 
      Wiesmuller, F. Grosse, and W. Deppert.</STRONG> 1999. The dual role model 
      for p53 in maintaining genomic integrity. Cell. Mol. Life Sci. 
      <B>55</B><B>:</B>12-27<!-- HIGHWIRE ID="21:20:6768:35" --><A 
      href="/cgi/external_ref?access_num=10.1007/s000180050266&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=10065148&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B36>36.</A> 
    <TD vAlign=top><STRONG>Jeng, Y. M., M. Z. Wu, T. L. Mao, M. H. Chang, and 
      H. C. Hsu.</STRONG> 2000. Somatic mutations of beta-catenin play a crucial 
      role in the tumorigenesis of sporadic hepatoblastoma. Cancer Lett. 
      <B>152</B><B>:</B>45-51<!-- HIGHWIRE ID="21:20:6768:36" --><A 
      href="/cgi/external_ref?access_num=10.1016/S0304-3835(99)00433-4&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=10754205&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B37>37.</A> 
    <TD vAlign=top><STRONG>Kam, Z., M. Jones, O. H. Chen, D. Agad, and J. W. 
      Sedat.</STRONG> 1993. Design and construction of an optimal illumination 
      system for quantitative wide-field multi-dimensional microscopy. 
      Bioimaging <B>1</B><B>:</B>71-81<!-- HIGHWIRE ID="21:20:6768:37" --><A 
      href="/cgi/external_ref?access_num=10.1002/1361-6374(199306)1:2<71::AID-BIO2>3.0.CO;2-#&amp;link_type=DOI">[CrossRef]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B38>38.</A> 
    <TD vAlign=top><STRONG>Kikuchi, A.</STRONG> 2000. Regulation of 
      beta-catenin signaling in the Wnt pathway. Biochem. Biophys. Res. Commun. 
      <B>268</B><B>:</B>243-248<!-- HIGHWIRE ID="21:20:6768:38" --><A 
      href="/cgi/external_ref?access_num=10.1006/bbrc.1999.1860&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=10679188&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B39>39.</A> 
    <TD vAlign=top><STRONG>Kikuchi-Yanoshita, R., M. Konishi, S. Ito, M. Seki, 
      K. Tanaka, Y. Maeda, H. Iino, M. Fukayama, M. T. Koike. Mori, et 
      al.</STRONG> 1992. Genetic changes of both p53 alleles associated with the 
      conversion from colorectal adenoma to early carcinoma in familial 
      adenomatous polyposis and non-familial adenomatous polyposis patients. 
      Cancer Res. 
      <B>52</B><B>:</B>3965-3971<!-- HIGHWIRE ID="21:20:6768:39" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=canres&amp;resid=52/14/3965">[Abstract]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B40>40.</A> 
    <TD vAlign=top><STRONG>Kinzler, K. W., and B. Vogelstein.</STRONG> 1996. 
      Lessons from hereditary colorectal cancer. Cell <B>87</B><B>:</B>159-170<!-- HIGHWIRE ID="21:20:6768:40" --><A 
      href="/cgi/external_ref?access_num=8861899&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B41>41.</A> 
    <TD vAlign=top><STRONG>Kitagawa, M., S. Hatakeyama, M. Shirane, M. 
      Matsumoto, N. Ishida, K. Hattori, I. Nakamichi, A. Kikuchi, K. Nakayama, 
      and K. Nakayama.</STRONG> 1999. An F-box protein, FWD1, mediates 
      ubiquitin-dependent proteolysis of beta-catenin. EMBO J. 
      <B>18</B><B>:</B>2401-2410<!-- HIGHWIRE ID="21:20:6768:41" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=emboj&amp;resid=18/9/2401"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B42>42.</A> 
    <TD vAlign=top><STRONG>Koch, A., D. Denkhaus, S. Albrecht, I. Leuschner, 
      D. von Schweinitz, and T. Pietsch.</STRONG> 1999. Childhood 
      hepatoblastomas frequently carry a mutated degradation targeting box of 
      the beta-catenin gene. Cancer Res. <B>59</B><B>:</B>269-273<!-- HIGHWIRE ID="21:20:6768:42" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=canres&amp;resid=59/2/269"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B43>43.</A> 
    <TD vAlign=top><STRONG>Koesters, R., R. Ridder, A. Kopp-Schneider, D. 
      Betts, V. Adams, F. Niggli, J. Briner, and M. von Knebel 
      Doeberitz.</STRONG> 1999. Mutational activation of the beta-catenin 
      proto-oncogene is a common event in the development of Wilms' tumors. 
      Cancer Res. 
      <B>59</B><B>:</B>3880-3882<!-- HIGHWIRE ID="21:20:6768:43" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=canres&amp;resid=59/16/3880"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B44>44.</A> 
    <TD vAlign=top><STRONG>Laurent-Puig, P., H. Blons, and P. H. 
      Cugnenc.</STRONG> 1999. Sequence of molecular genetic events in colorectal 
      tumorigenesis. Eur. J.&nbsp;Cancer Prev. <B>9</B>(Suppl. 
      1)<B></B><B>:</B>S39-S47<!-- HIGHWIRE ID="21:20:6768:44" --><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B45>45.</A> 
    <TD vAlign=top><STRONG>Levine, A. J.</STRONG> 1997. p53, the cellular 
      gatekeeper for growth and division. Cell <B>88</B><B>:</B>323-331<!-- HIGHWIRE ID="21:20:6768:45" --><A 
      href="/cgi/external_ref?access_num=9039259&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B46>46.</A> 
    <TD vAlign=top><STRONG>Liu, C., Y. Kato, Z. Zhang, V. Do, B. Yankner, and 
      X. He.</STRONG> 1999. Beta-Trcp couples beta-catenin 
      phosphorylation-degradation and regulates Xenopus axis formation. Proc. 
      Natl. Acad. Sci. USA <B>96</B><B>:</B>6273-6278<!-- HIGHWIRE ID="21:20:6768:46" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=pnas&amp;resid=96/11/6273"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B47>47.</A> 
    <TD vAlign=top><STRONG>Liu, J., J. Stevens, C. Rote, H. Yost, Y. Hu, K. 
      Neufeld, R. White, and N. Matsunami.</STRONG> 2001. Siah-1 mediates a 
      novel beta-catenin degradation pathway linking p53 to the adenomatous 
      polyposis coli protein. Mol. Cell <B>7</B><B>:</B>927-936<!-- HIGHWIRE ID="21:20:6768:47" --><A 
      href="/cgi/external_ref?access_num=10.1016/S1097-2765(01)00241-6&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=11389840&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B48>48.</A> 
    <TD vAlign=top><STRONG>Mann, B., M. Gelos, A. Siedow, M. Hanski, A. 
      Gratchev, M. Ilyas, W. Bodmer, M. Moyer, E. Riecken, and H. Buhr.</STRONG> 
      1999. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor 
      signaling in human colorectal carcinomas. Proc. Natl. Acad. Sci. USA 
      <B>96</B><B>:</B>1603-1608<!-- HIGHWIRE ID="21:20:6768:48" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=pnas&amp;resid=96/4/1603"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B49>49.</A> 
    <TD vAlign=top><STRONG>Mao, B., W. Wu, Y. Li, D. Hoppe, P. Stannek, A. 
      Glinka, and C. Niehrs.</STRONG> 2001. LDL-receptor-related protein 
      6&nbsp;is a receptor for Dickkopf proteins. Nature 
      <B>411</B><B>:</B>321-325<!-- HIGHWIRE ID="21:20:6768:49" --><A 
      href="/cgi/external_ref?access_num=10.1038/35077108&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=11357136&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B50>50.</A> 
    <TD vAlign=top><STRONG>Marin, M. C., C. A. Jost, M. S. Irwin, J. A. 
      DeCaprio, D. Caput, and W. G. Kaelin, Jr.</STRONG> 1998. Viral 
      oncoproteins discriminate between p53 and the p53 homolog p73. Mol. Cell. 
      Biol. <B>18</B><B>:</B>6316-6324<!-- HIGHWIRE ID="21:20:6768:50" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=mcb&amp;resid=18/11/6316"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B51>51.</A> 
    <TD vAlign=top><STRONG>Matsuzawa, S.-I., and J. Reed.</STRONG> 2001. 
      Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin 
      degradation linked to p53 responses. Mol. Cell <B>7</B><B>:</B>915-926<!-- HIGHWIRE ID="21:20:6768:51" --><A 
      href="/cgi/external_ref?access_num=10.1016/S1097-2765(01)00242-8&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=11389839&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B52>52.</A> 
    <TD vAlign=top><STRONG>Mirabelli-Primdahl, L., R. Gryfe, H. Kim, A. 
      Millar, C. Luceri, D. Dale, E. Holowaty, B. Bapat, S. Gallinger, and M. 
      Redston.</STRONG> 1999. Beta-catenin mutations are specific for colorectal 
      carcinomas with microsatellite instability but occur in endometrial 
      carcinomas irrespective of mutator pathway. Cancer Res. 
      <B>59</B><B>:</B>3346-3351<!-- HIGHWIRE ID="21:20:6768:52" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=canres&amp;resid=59/14/3346"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B53>53.</A> 
    <TD vAlign=top><STRONG>Miyagishi, M., R. Fujii, M. Hatta, E. Yoshida, N. 
      Araya, A. Nagafuchi, S. Ishihara, T. Nakajima, and A. Fukamizu.</STRONG> 
      2000. Regulation of lef-mediated transcription and p53-dependent pathway 
      by associating beta-catenin with CBP/p300. J. Biol. Chem. 
      <B>275</B><B>:</B>35170-35175<!-- HIGHWIRE ID="21:20:6768:53" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=jbc&amp;resid=275/45/35170"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B54>54.</A> 
    <TD vAlign=top><STRONG>Miyoshi, Y., K. Iwao, G. Nawa, H. Yoshikawa, T. 
      Ochi, and Y. Nakamura.</STRONG> 1998. Frequent mutations in the 
      beta-catenin gene in desmoid tumors from patients without familial 
      adenomatous polyposis. Oncol. Res. <B>10</B><B>:</B>591-594<!-- HIGHWIRE ID="21:20:6768:54" --><A 
      href="/cgi/external_ref?access_num=10367940&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B55>55.</A> 
    <TD vAlign=top><STRONG>Miyoshi, Y., H. Nagase, H. Ando, A. Horii, S. 
      Ichii, S. Nakatsuru, T. Aoki, Y. Miki, T. Mori, and Y. Nakamura.</STRONG> 
      1992. Somatic mutations of the APC gene in colorectal tumors: mutation 
      cluster region in the APC gene. Hum. Mol. Genet. <B>1</B><B>:</B>229-233<!-- HIGHWIRE ID="21:20:6768:55" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=hmg&amp;resid=1/4/229">[Abstract]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B56>56.</A> 
    <TD vAlign=top><STRONG>Molenaar, M., M. van de Wetering, M. Oosterwegel, 
      J. Peterson-Maduro, S. Godsave, V. Korinek, J. Roose, O. Destree, and H. 
      Clevers.</STRONG> 1996. XTcf-3 transcription factor mediates 
      beta-catenin-induced axis formation in Xenopus embryos. Cell 
      <B>86</B><B>:</B>391-399<!-- HIGHWIRE ID="21:20:6768:56" --><A 
      href="/cgi/external_ref?access_num=8756721&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B57>57.</A> 
    <TD vAlign=top><STRONG>Morin, P., A. Sparks, V. Korinek, N. Barker, H. 
      Clevers, B. Vogelstein, and K. Kinzler.</STRONG> 1997. Activation of 
      beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or 
      APC. Science <B>275</B><B>:</B>1787-1790<!-- HIGHWIRE ID="21:20:6768:57" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=sci&amp;resid=275/5307/1787"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B58>58.</A> 
    <TD vAlign=top><STRONG>Munemitsu, S., I. Albert, B. Souza, B. Rubinfeld, 
      and P. Polakis.</STRONG> 1995. Regulation of intracellular beta-catenin 
      levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. 
      Proc. Natl. Acad. Sci. USA <B>92</B><B>:</B>3046-3050<!-- HIGHWIRE ID="21:20:6768:58" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=pnas&amp;resid=92/7/3046">[Abstract]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B59>59.</A> 
    <TD vAlign=top><STRONG>Narayan, S., and A. S. Jaiswal.</STRONG> 1997. 
      Activation of adenomatous polyposis coli (APC) gene expression by the 
      DNA-alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine requires p53. J. 
      Biol. Chem. <B>272</B><B>:</B>30619-30622<!-- HIGHWIRE ID="21:20:6768:59" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=jbc&amp;resid=272/49/30619"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B60>60.</A> 
    <TD vAlign=top><STRONG>Nigro, J. M., S. J. Baker, A. C. Preisinger, J. M. 
      Jessup, R. Hostetter, K. Cleary, S. H. Bigner, N. Davidson, S. Baylin, P. 
      Devilee, T. Glover, F. S. Collins, A. Weston, R. Modali, C. C. Harris, and 
      B. Vogelstein.</STRONG> 1989. Mutations in the p53 gene occur in diverse 
      human tumour types. Nature <B>342</B><B>:</B>705-708<!-- HIGHWIRE ID="21:20:6768:60" --><A 
      href="/cgi/external_ref?access_num=2531845&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B61>61.</A> 
    <TD vAlign=top><STRONG>Oren, M.</STRONG> 1999. Regulation of the p53 tumor 
      suppressor protein. J. Biol. Chem. <B>274</B><B>:</B>36031-36034<!-- HIGHWIRE ID="21:20:6768:61" --><A 
      href="/cgi/ijlink?linkType=FULL&amp;journalCode=jbc&amp;resid=274/51/36031"><NOBR>[<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B62>62.</A> 
    <TD vAlign=top><STRONG>Orford, K., C. Orford, and S. Byers.</STRONG> 1999. 
      Exogenous expression of beta-catenin regulates contact inhibition, 
      anchorage independent growth, anoikis, and radiation-induced cell cycle 
      arrest. J. Cell Biol. <B>146</B><B>:</B>855-867<!-- HIGHWIRE ID="21:20:6768:62" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=jcb&amp;resid=146/4/855"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B63>63.</A> 
    <TD vAlign=top><STRONG>Oshima, M., H. Oshima, K. Kitagawa, M. Kobayashi, 
      C. Itakura, and M. Taketo.</STRONG> 1995. Loss of Apc heterozygosity and 
      abnormal tissue building in nascent intestinal polyps in mice carrying a 
      truncated Apc gene. Proc. Natl. Acad. Sci. USA <B>92</B><B>:</B>4482-4486<!-- HIGHWIRE ID="21:20:6768:63" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=pnas&amp;resid=92/10/4482">[Abstract]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B64>64.</A> 
    <TD vAlign=top><STRONG>Peifer, M.</STRONG> 1997. Beta-catenin as oncogene: 
      the smoking gun. Science <B>275</B><B>:</B>1752-1753<!-- HIGHWIRE ID="21:20:6768:64" --><A 
      href="/cgi/ijlink?linkType=FULL&amp;journalCode=sci&amp;resid=275/5307/1752"><NOBR>[<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B65>65.</A> 
    <TD vAlign=top><STRONG>Polakis, P.</STRONG> 1999. The oncogenic activation 
      of beta-catenin. Curr. Opin. Genet. Dev. <B>9</B><B>:</B>15-21<!-- HIGHWIRE ID="21:20:6768:65" --><A 
      href="/cgi/external_ref?access_num=10.1016/S0959-437X(99)80003-3&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=10072352&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B66>66.</A> 
    <TD vAlign=top><STRONG>Polakis, P.</STRONG> 2000. Wnt signaling and 
      cancer. Genes Dev. <B>14</B><B>:</B>1837-1851<!-- HIGHWIRE ID="21:20:6768:66" --><A 
      href="/cgi/ijlink?linkType=FULL&amp;journalCode=genesdev&amp;resid=14/15/1837"><NOBR>[<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B67>67.</A> 
    <TD vAlign=top><STRONG>Renard, C. A., G. Fourel, M. P. Bralet, C. Degott, 
      A. De La Coste, C. Perret, P. Tiollais, and M. A. Buendia.</STRONG> 2000. 
      Hepatocellular carcinoma in WHV/N-myc2 transgenic mice: oncogenic 
      mutations of beta-catenin and synergistic effect of p53 null alleles. 
      Oncogene <B>19</B><B>:</B>2678-2686<!-- HIGHWIRE ID="21:20:6768:67" --><A 
      href="/cgi/external_ref?access_num=10.1038/sj.onc.1203617&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=10851067&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B68>68.</A> 
    <TD vAlign=top><STRONG>Roose, J., and H. Clevers.</STRONG> 1999. TCF 
      transcription factors: molecular switches in carcinogenesis. Biochim. 
      Biophys. Acta <B>1424</B><B>:</B>M23-M37<!-- HIGHWIRE ID="21:20:6768:68" --><A 
      href="/cgi/external_ref?access_num=10.1016/S0304-419X(99)00026-8&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=10528152&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B69>69.</A> 
    <TD vAlign=top><STRONG>Roperch, J. P., V. Alvaro, S. Prieur, M. Tuynder, 
      M. Nemani, F. Lethrosne, L. Piouffre, M. C. Gendron, D. Israeli, J. 
      Dausset, M. Oren, R. Amson, and A. Telerman.</STRONG> 1998. Inhibition of 
      presenilin 1&nbsp;expression is promoted by p53 and p21WAF-1 and results 
      in apoptosis and tumor suppression. Nat. Med. <B>4</B><B>:</B>835-838<!-- HIGHWIRE ID="21:20:6768:69" --><A 
      href="/cgi/external_ref?access_num=9662377&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B70>70.</A> 
    <TD vAlign=top><STRONG>Rubinfeld, B., P. Robbins, M. El-Gamil, I. Albert, 
      E. Porfiri, and P. Polakis.</STRONG> 1997. Stabilization of beta-catenin 
      by genetic defects in melanoma cell lines. Science 
      <B>275</B><B>:</B>1790-1792<!-- HIGHWIRE ID="21:20:6768:70" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=sci&amp;resid=275/5307/1790"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B71>71.</A> 
    <TD vAlign=top><STRONG>Sadot, E., I. Simcha, K. Iwai, A. Ciechanover, B. 
      Geiger, and A. Ben-Ze'ev.</STRONG> 2000. Differential interaction of 
      plakoglobin and beta-catenin with the ubiquitin-proteasome system. 
      Oncogene <B>19</B><B>:</B>1992-2001<!-- HIGHWIRE ID="21:20:6768:71" --><A 
      href="/cgi/external_ref?access_num=10.1038/sj.onc.1203519&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=10803460&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B72>72.</A> 
    <TD vAlign=top><STRONG>Sherr, C. J., and J. D. Weber.</STRONG> 2000. The 
      ARF/p53 pathway. Curr. Opin. Genet. Dev. <B>10</B><B>:</B>94-99<!-- HIGHWIRE ID="21:20:6768:72" --><A 
      href="/cgi/external_ref?access_num=10.1016/S0959-437X(99)00038-6&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=10679383&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B73>73.</A> 
    <TD vAlign=top><STRONG>Shtutman, M., J. Zhurinsky, I. Simcha, C. Albanese, 
      M. D'Amico, R. Pestell, and A. Ben-Ze'ev.</STRONG> 1999. The cyclin D1 
      gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. 
      USA <B>96</B><B>:</B>5522-5527<!-- HIGHWIRE ID="21:20:6768:73" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=pnas&amp;resid=96/10/5522"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B74>74.</A> 
    <TD vAlign=top><STRONG>Simcha, I., M. Shtutman, D. Salomon, J. Zhurinsky, 
      E. Sadot, B. Geiger, and A. Ben-Ze'ev.</STRONG> 1998. Differential nuclear 
      translocation and transactivation potential of beta-catenin and 
      plakoglobin. J. Cell Biol. <B>141</B><B>:</B>1433-1448<!-- HIGHWIRE ID="21:20:6768:74" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=jcb&amp;resid=141/6/1433"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B75>75.</A> 
    <TD vAlign=top><STRONG>Simms, L. A., G. Radford-Smith, K. G. Biden, R. 
      Buttenshaw, M. Cummings, J. R. Jass, J. Young, S. J. Meltzer, and B. A. 
      Leggett.</STRONG> 1998. Reciprocal relationship between the tumor 
      suppressors p53 and BAX in primary colorectal cancers. Oncogene 
      <B>17</B><B>:</B>2003-2008<!-- HIGHWIRE ID="21:20:6768:75" --><A 
      href="/cgi/external_ref?access_num=10.1038/sj.onc.1202109&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=9788444&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B76>76.</A> 
    <TD vAlign=top><STRONG>Sionov, R. V., and Y. Haupt.</STRONG> 1999. The 
      cellular response to p53: the decision between life and death. Oncogene 
      <B>18</B><B>:</B>6145-6157<!-- HIGHWIRE ID="21:20:6768:76" --><A 
      href="/cgi/external_ref?access_num=10.1038/sj.onc.1203130&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=10557106&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B77>77.</A> 
    <TD vAlign=top><STRONG>Sparks, A., P. Morin, B. Vogelstein, and K. 
      Kinzler.</STRONG> 1998. Mutational analysis of the APC/beta-catenin/Tcf 
      pathway in colorectal cancer. Cancer Res. <B>58</B><B>:</B>1130-1134<!-- HIGHWIRE ID="21:20:6768:77" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=canres&amp;resid=58/6/1130">[Abstract]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B78>78.</A> 
    <TD vAlign=top><STRONG>Subler, M. A., D. W. Martin, and S. Deb.</STRONG> 
      1992. Inhibition of viral and cellular promoters by human wild-type p53. 
      J. Virol. <B>66</B><B>:</B>4757-4762<!-- HIGHWIRE ID="21:20:6768:78" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=jvi&amp;resid=66/8/4757">[Abstract]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B79>79.</A> 
    <TD vAlign=top><STRONG>Takemaru, K., and R. Moon.</STRONG> 2000. The 
      transcriptional coactivator CBP interacts with beta-catenin to activate 
      gene expression. J. Cell Biol. <B>149</B><B>:</B>249-254<!-- HIGHWIRE ID="21:20:6768:79" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=jcb&amp;resid=149/2/249"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B80>80.</A> 
    <TD vAlign=top><STRONG>Tetsu, O., and F. McCormick.</STRONG> 1999. 
      Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. 
      Nature <B>398</B><B>:</B>422-426<!-- HIGHWIRE ID="21:20:6768:80" --><A 
      href="/cgi/external_ref?access_num=10.1038/18884&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=10201372&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B81>81.</A> 
    <TD vAlign=top><STRONG>Van de Craen, M., G. Berx, I. Van den Brande, W. 
      Fiers, W. Declercq, and P. Vandenabeele.</STRONG> 1999. Proteolytic 
      cleavage of beta-catenin by caspases: an in vitro analysis. FEBS Lett. 
      <B>458</B><B>:</B>167-170<!-- HIGHWIRE ID="21:20:6768:81" --><A 
      href="/cgi/external_ref?access_num=10.1016/S0014-5793(99)01153-9&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=10481058&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B82>82.</A> 
    <TD vAlign=top><STRONG>van de Wetering, M., R. Cavallo, D. Dooijes, M. van 
      Beest, J. van Es, J. Loureiro, A. Ypma, D. Hursh, T. Jones, A. Bejsovec, 
      M. Peifer, M. Mortin, and H. Clevers.</STRONG> 1997. Armadillo coactivates 
      transcription driven by the product of the Drosophila segment polarity 
      gene dTCF. Cell <B>88</B><B>:</B>789-799<!-- HIGHWIRE ID="21:20:6768:82" --><A 
      href="/cgi/external_ref?access_num=9118222&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B83>83.</A> 
    <TD vAlign=top><STRONG>Voeller, H., C. Truica, and E. Gelmann.</STRONG> 
      1998. Beta-catenin mutations in human prostate cancer. Cancer Res. 
      <B>58</B><B>:</B>2520-2523<!-- HIGHWIRE ID="21:20:6768:83" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=canres&amp;resid=58/12/2520">[Abstract]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B84>84.</A> 
    <TD vAlign=top><STRONG>Vojtesek, B., J. Bartek, C. A. Midgley, and D. P. 
      Lane.</STRONG> 1992. An immunochemical analysis of the human nuclear 
      phosphoprotein p53. New monoclonal antibodies and epitope mapping using 
      recombinant p53. J. Immunol. Methods <B>151</B><B>:</B>237-244<!-- HIGHWIRE ID="21:20:6768:84" --><A 
      href="/cgi/external_ref?access_num=1378473&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B85>85.</A> 
    <TD vAlign=top><STRONG>Wang, J., J. Shou, and X. Chen.</STRONG> 2000. 
      Dickkopf-1, an inhibitor of the Wnt signaling pathway, is induced by p53. 
      Oncogene <B>19</B><B>:</B>1843-1848<!-- HIGHWIRE ID="21:20:6768:85" --><A 
      href="/cgi/external_ref?access_num=10.1038/sj.onc.1203503&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=10777218&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B86>86.</A> 
    <TD vAlign=top><STRONG>Webster, G. A., and N. D. Perkins.</STRONG> 1999. 
      Transcriptional cross talk between NF-kappaB and p53. Mol. Cell. Biol. 
      <B>19</B><B>:</B>3485-3495<!-- HIGHWIRE ID="21:20:6768:86" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=mcb&amp;resid=19/5/3485"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B87>87.</A> 
    <TD vAlign=top><STRONG>Wei, Y., M. Fabre, S. Branchereau, F. Gauthier, G. 
      Perilongo, and M. A. Buendia.</STRONG> 2000. Activation of beta-catenin in 
      epithelial and mesenchymal hepatoblastomas. Oncogene 
      <B>19</B><B>:</B>498-504<!-- HIGHWIRE ID="21:20:6768:87" --><A 
      href="/cgi/external_ref?access_num=10.1038/sj.onc.1203356&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=10698519&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B88>88.</A> 
    <TD vAlign=top><STRONG>Winston, J., P. Strack, P. Beer-Romero, C. Chu, S. 
      Elledge, and J. Harper.</STRONG> 1999. The SCFbeta-TRCP-ubiquitin ligase 
      complex associates specifically with phosphorylated destruction motifs in 
      IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination 
      in vitro. Genes Dev. <B>13</B><B>:</B>270-283<!-- HIGHWIRE ID="21:20:6768:88" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=genesdev&amp;resid=13/3/270"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B89>89.</A> 
    <TD vAlign=top><STRONG>Wright, K., P. Wilson, S. Morland, I. Campbell, M. 
      Walsh, T. Hurst, B. Ward, M. Cummings, and G. Chenevix-Trench.</STRONG> 
      1999. Beta-catenin mutation and expression analysis in ovarian cancer: 
      exon 3&nbsp;mutations and nuclear translocation in 16% of endometrioid 
      tumours. Int. J.&nbsp;Cancer <B>82</B><B>:</B>625-629<!-- HIGHWIRE ID="21:20:6768:89" --><A 
      href="/cgi/external_ref?access_num=10.1002/(SICI)1097-0215(19990827)82:5<625::AID-IJC1>3.3.CO;2-U&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=10417756&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B90>90.</A> 
    <TD vAlign=top><STRONG>Xu, L., R. B. Corcoran, J. W. Welsh, D. Pennica, 
      and A. J. Levine.</STRONG> 2000. WISP-1 is a Wnt-1- and 
      beta-catenin-responsive oncogene. Genes Dev. <B>14</B><B>:</B>585-595<!-- HIGHWIRE ID="21:20:6768:90" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=genesdev&amp;resid=14/5/585"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B91>91.</A> 
    <TD vAlign=top><STRONG>Yost, C., M. Torres, J. Miller, E. Huang, D. 
      Kimelman, and R. Moon.</STRONG> 1996. The axis-inducing activity, 
      stability, and subcellular distribution of beta-catenin is regulated in 
      Xenopus embryos by glycogen synthase kinase 3. Genes Dev. 
      <B>10</B><B>:</B>1443-1454<!-- HIGHWIRE ID="21:20:6768:91" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=genesdev&amp;resid=10/12/1443">[Abstract]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B92>92.</A> 
    <TD vAlign=top><STRONG>Zhang, Z., H. Hartmann, V. Do, D. Abramowski, C. 
      Sturchler-Pierrat, M. Staufenbiel, B. Sommer, M. van de Wetering, H. 
      Clevers, P. Saftig, B. De Strooper, X. He, and B. Yankner.</STRONG> 1998. 
      Destabilization of beta-catenin by mutations in presenilin-1 potentiates 
      neuronal apoptosis. Nature <B>395</B><B>:</B>698-702<!-- HIGHWIRE ID="21:20:6768:92" --><A 
      href="/cgi/external_ref?access_num=10.1038/27208&amp;link_type=DOI">[CrossRef]</A><A 
      href="/cgi/external_ref?access_num=9790190&amp;link_type=MED">[Medline]</A><!-- /HIGHWIRE -->. 
    </TD>
  <TR>
    <TD vAlign=top><A name=B93>93.</A> 
    <TD vAlign=top><STRONG>Zhurinsky, J., M. Shtutman, and A. 
      Ben-Ze'ev.</STRONG> 2000. Differential mechanisms of LEF/TCF 
      family-dependent transcriptional activation by beta-catenin and 
      plakoglobin. Mol. Cell. Biol. <B>20</B><B>:</B>4238-4252<!-- HIGHWIRE ID="21:20:6768:93" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=mcb&amp;resid=20/12/4238"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B94>94.</A> 
    <TD vAlign=top><STRONG>Zhurinsky, J., M. Shtutman, and A. 
      Ben-Ze'ev.</STRONG> 2000. Plakoglobin and <IMG align=bottom alt="beta " 
      src="/math/12pt/normal/beta.gif">-catenin: protein interactions, 
      regulation and biological roles. J. Cell Sci. <B>113</B><B>:</B>3127-3139<!-- HIGHWIRE ID="21:20:6768:94" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=joces&amp;resid=113/18/3127"><NOBR>[Abstract/<FONT 
      color=#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE -->. 
</TD>
  <TR>
    <TD vAlign=top><A name=B95>95.</A> 
    <TD vAlign=top><STRONG>Zurawel, R., S. Chiappa, C. Allen, and C. 
      Raffel.</STRONG> 1998. Sporadic medulloblastomas contain oncogenic 
      beta-catenin mutations. Cancer Res. <B>58</B><B>:</B>896-899<!-- HIGHWIRE ID="21:20:6768:95" --><A 
      href="/cgi/ijlink?linkType=ABST&amp;journalCode=canres&amp;resid=58/5/896">[Abstract]</A><!-- /HIGHWIRE -->. 
    </TD></TR></TBODY></TABLE>
<P>
<HR>
<FONT size=-1>Molecular and Cellular Biology, October 2001, p. 6768-6781, Vol. 
21, No. 20<BR>0270-7306/01/$04.00+0 &nbsp;&nbsp;DOI: 
10.1128/MCB.21.20.6768-6781.2001<BR><A href="/misc/terms.shtml">Copyright Â© 
2001</A>, <A href="http://www.asmusa.org">American Society for Microbiology</A>. 
All rights reserved.</FONT> <!-- /COPYRIGHT --><!--

   Pages created by the Electronic Press Engine from

		Atypon Systems, Inc.

   Visit http://www.atypon.com/

--></VARDEF><BR 
clear=all><A name=otherarticles><!-- null --></A>
<P><FONT size=+2><STRONG>This article has been cited by other 
articles:</STRONG></FONT> 
<P>
<UL>
  <LI>Chowdhury, I. H., Radonovich, M., Mahieux, R., Pise-Masison, C., 
  Muralidhar, S., Brady, J. N. (2003). p53 facilitates degradation of human 
  T-cell leukaemia virus type I Tax-binding protein through a 
  proteasome-dependent pathway. <EM>J Gen Virol</EM> 84: 897-906 <NOBR><A 
  href="http://vir.sgmjournals.org/cgi/content/abstract/84/4/897">[Abstract]</A> 
  <A href="http://vir.sgmjournals.org/cgi/content/full/84/4/897">[Full Text]</A> 
  &nbsp;</NOBR> 
  <LI>OREN, M., DAMALAS, A., GOTTLIEB, T., MICHAEL, D., TAPLICK, J., LEAL, J. F. 
  M., MAYA, R., MOAS, M., SEGER, R., TAYA, Y., BEN-ZE'EV, A. (2002). Regulation 
  of p53: Intricate Loops and Delicate Balances. <EM>Annals NYAS Online</EM> 
  973: 374-383 <NOBR><A 
  href="http://www.annalsnyas.org/cgi/content/abstract/973/1/374">[Abstract]</A> 
  <A href="http://www.annalsnyas.org/cgi/content/full/973/1/374">[Full Text]</A> 
  &nbsp;</NOBR> 
  <LI>Kotsinas, A., Evangelou, K., Zacharatos, P., Kittas, C., Gorgoulis, V. G. 
  (2002). Proliferation, but Not Apoptosis, Is Associated with Distinct 
  {beta}-Catenin Expression Patterns in Non-Small-Cell Lung Carcinomas : 
  Relationship with Adenomatous Polyposis Coli and G1-to S-Phase Cell-Cycle 
  Regulators. <EM>Am J Pathol</EM> 161: 1619-1634 <NOBR><A 
  href="http://ajp.amjpathol.org/cgi/content/abstract/161/5/1619">[Abstract]</A> 
  <A href="http://ajp.amjpathol.org/cgi/content/full/161/5/1619">[Full Text]</A> 
  &nbsp;</NOBR> 
  <LI>Shtutman, M., Zhurinsky, J., Oren, M., Levina, E., Ben-Ze'ev, A. (2002). 
  PML Is a Target Gene of {beta}-Catenin and Plakoglobin, and Coactivates 
  {beta}-Catenin-mediated Transcription. <EM>Cancer Res</EM> 62: 5947-5954 
  <NOBR><A 
  href="http://cancerres.aacrjournals.org/cgi/content/abstract/62/20/5947">[Abstract]</A> 
  <A href="http://cancerres.aacrjournals.org/cgi/content/full/62/20/5947">[Full 
  Text]</A> &nbsp;</NOBR> 
  <LI>Watcharasit, P., Bijur, G. N., Zmijewski, J. W., Song, L., Zmijewska, A., 
  Chen, X., Johnson, G. V. W., Jope, R. S. (2002). Direct, activating 
  interaction between glycogen synthase kinase-3beta and p53 after DNA damage. 
  <EM>Proc. Natl. Acad. Sci. U. S. A.</EM> 99: 7951-7955 <NOBR><A 
  href="http://www.pnas.org/cgi/content/abstract/99/12/7951">[Abstract]</A> <A 
  href="http://www.pnas.org/cgi/content/full/99/12/7951">[Full Text]</A> 
  &nbsp;</NOBR> 
  <LI>You, Z., Saims, D., Chen, S., Zhang, Z., Guttridge, D. C., Guan, K.-l., 
  MacDougald, O. A., Brown, A. M.C., Evan, G., Kitajewski, J., Wang, C.-Y. 
  (2002). Wnt signaling promotes oncogenic transformation by inhibiting 
  c-Myc-induced apoptosis. <EM>J. Cell Biol.</EM> 157: 429-440 <NOBR><A 
  href="http://www.jcb.org/cgi/content/abstract/157/3/429">[Abstract]</A> <A 
  href="http://www.jcb.org/cgi/content/full/157/3/429">[Full Text]</A> 
  &nbsp;</NOBR> 
  <LI>Conacci-Sorrell, M., Zhurinsky, J., Ben-Ze'ev, A. (2002). The 
  cadherin-catenin adhesion system in signaling and cancer. <EM>J. Clin. 
  Invest.</EM> 109: 987-991 <NOBR><A 
  href="http://www.jci.org/cgi/content/full/109/8/987">[Full Text]</A> 
  &nbsp;</NOBR> </LI></UL><BR clear=all><BR clear=all><!-- beginning of outer tables -->
<TABLE align=right border=1 cellPadding=4 NOWRAP VSPACE="4" HSPACE="4">
  <TBODY>
  <TR>
    <TD align=left noWrap><!-- beginning of inner table -->
      <TABLE border=0 cellPadding=0 cellSpacing=1 NOWRAP>
        <TBODY>
        <TR>
          <TD><IMG align=baseline alt="" border=0 height=11 
            src="/icons/toc/rarrowsm.gif" width=9><FONT size=-1> <A 
            href="/cgi/content/abstract/21/20/6768">Abstract of this Article</A> 
            (<IMG src="/icons/shared/toc/free.gif">) </FONT></TD></TR>
        <TR>
          <TD><IMG align=baseline alt="" border=0 height=11 
            src="/icons/toc/rarrowsm.gif" width=9><FONT size=-1> <STRONG><A 
            href="/cgi/reprint/21/20/6768">Reprint (PDF) Version of this 
            Article</A> </FONT></STRONG></TD></TR>
        <TR>
          <TD><IMG align=baseline alt="" border=0 height=11 
            src="/icons/toc/rarrowsm.gif" width=9><FONT size=-1> Similar 
            articles found in:<BR><IMG align=baseline alt="" border=0 height=9 
            src="/icons/spacer.gif" width=9><IMG align=baseline alt="" border=0 
            height=9 src="/icons/spacer.gif" width=9><A 
            href="/cgi/search?qbe=mcb;21/20/6768&amp;journalcode=mcb&amp;minscore=4000"><FONT 
            size=-1>MCB Online</FONT></A> <BR><IMG align=baseline alt="" 
            border=0 height=9 src="/icons/spacer.gif" width=9><IMG 
            align=baseline alt="" border=0 height=9 src="/icons/spacer.gif" 
            width=9><A 
            href="/cgi/external_ref?access_num=11564862&amp;link_type=MED_NBRS"><FONT 
            size=-1>PubMed</FONT></A> </FONT></TD></TR>
        <TR>
          <TD><IMG align=baseline alt="" border=0 height=11 
            src="/icons/toc/rarrowsm.gif" width=9><FONT size=-1> <A 
            href="/cgi/external_ref?access_num=11564862&amp;link_type=PUBMED">PubMed 
            Citation</A> </FONT></TD></TR>
        <TR>
          <TD><IMG align=baseline alt="" border=0 height=11 
            src="/icons/toc/rarrowsm.gif" width=9><FONT size=-1> This Article 
            has been cited by: </FONT></TD></TR>
        <TR>
          <TD><IMG align=baseline alt="" border=0 height=11 
            src="/icons/toc/rarrowsm.gif" width=9><FONT size=-1> Search Medline 
            for articles by:<BR><IMG align=baseline alt="" border=0 height=9 
            src="/icons/spacer.gif" width=9><IMG align=baseline alt="" border=0 
            height=9 src="/icons/spacer.gif" width=9> <A 
            href="/cgi/external_ref?access_num=Sadot+E&amp;link_type=AUTHORSEARCH">Sadot, 
            E.</A> || <A 
            href="/cgi/external_ref?access_num=Ben-Ze%27ev+A&amp;link_type=AUTHORSEARCH">Ben-Ze'ev, 
            A.</A> </FONT></TD></TR>
        <TR>
          <TD><IMG align=baseline alt="" border=0 height=11 
            src="/icons/toc/rarrowsm.gif" width=9><FONT size=-1> Alert me when: 
            <BR><IMG align=baseline alt="" border=0 height=9 
            src="/icons/spacer.gif" width=9><IMG align=baseline alt="" border=0 
            height=9 src="/icons/spacer.gif" width=9><A 
            href="/cgi/alerts/ctalert?alertType=citedby&amp;addAlert=cited_by&amp;saveAlert=no&amp;cited_by_criteria_resid=mcb;21/20/6768&amp;return_type=article&amp;return_url=%2Fcgi%2Fcontent%2Ffull%2F21%2F20%2F6768"><FONT 
            size=-1>new articles cite this article</FONT></A><BR></FONT></TD></TR>
        <TR>
          <TD><IMG align=baseline alt="" border=0 height=11 
            src="/icons/toc/rarrowsm.gif" width=9><FONT size=-1> <A 
            href="/cgi/citmgr?gca=mcb;21/20/6768">Download to Citation 
            Manager</A> </FONT></TD></TR></TBODY></TABLE></TD></TR><!-- end of inner content box -->
  <TR>
    <TD align=left noWrap><FONT size=-1><IMG align=baseline alt="" border=0 
      height=11 src="/icons/toc/rarrowsm.gif" width=9><A 
      href="http://www.asmpress.org/">Books from ASM 
      Press</A><BR><STRONG></FONT></STRONG></TD></TR><!-- 1xxx --><!-- 2xxx --></TBODY></TABLE><!-- end of outer content box --><BR 
clear=all>
<P>
<HR align=left noShade width=450>
<A href="/" target=_top><IMG alt=Home border=0 height=15 
src="/icons/banner/homeACT.gif" width=40></A> <A href="/help/" target=_top><IMG 
alt=Help border=0 height=15 src="/icons/banner/helpACT.gif" width=36></A> <A 
href="/cgi/feedback" target=_top><IMG alt=[Feedback] border=0 height=15 
src="/icons/banner/feedbackACT.gif" width=56></A> <A href="/subscriptions/" 
target=_top><IMG alt="[For Subscribers]" border=0 height=15 
src="/icons/banner/subscriberACT.gif" width=95></A> <A 
href="/contents-by-date.0.shtml" target=_top><IMG alt=[Archive] border=0 
height=15 src="/icons/banner/archiveACT.gif" width=57></A> <A href="/search.dtl" 
target=_top><IMG alt=[Search] border=0 height=15 
src="/icons/banner/searchACT.gif" width=44></A> <A 
href="/content/vol21/issue20/index.shtml" target=_top><IMG alt=[Contents] 
border=0 height=15 src="/icons/banner/tocACT.gif" width=100></A> <BR>
<TABLE border=0 cellPadding=2 cellSpacing=2 width=450>
  <TBODY>
  <TR>
    <TH bgColor=#00664b noWrap width="33%"><FONT color=#ffffff 
      face=verdana,arial,helvetica size=-2><A href="http://jb.asm.org" 
      style="COLOR: #ffffff; TEXT-DECORATION: none">J. Bacteriol.</A></FONT></TH>
    <TH bgColor=#00664b noWrap width="33%"><FONT color=#ffffff 
      face=verdana,arial,helvetica size=-2><A href="http://jvi.asm.org" 
      style="COLOR: #ffffff; TEXT-DECORATION: none">J. Virol.</A></FONT></TH>
    <TH bgColor=#00664b noWrap width="33%"><FONT color=#ffffff 
      face=verdana,arial,helvetica size=-2><A href="http://ec.asm.org" 
      style="COLOR: #ffffff; TEXT-DECORATION: none">Eukaryot. 
  Cell</A></FONT></TH></TR></TBODY></TABLE>
<TABLE border=0 cellPadding=2 cellSpacing=2 width=450>
  <TBODY>
  <TR>
    <TH bgColor=#00664b noWrap width="50%"><FONT color=#ffffff 
      face=verdana,arial,helvetica size=-2><A href="http://mmbr.asm.org" 
      style="COLOR: #ffffff; TEXT-DECORATION: none">Microbio. Mol. Bio. 
      Review</A></FONT></TH>
    <TH align=middle bgColor=#00664b noWrap width="50%"><FONT color=#ffffff 
      face=verdana,arial,helvetica size=-2><A href="http://journals.asm.org" 
      style="COLOR: #ffffff; TEXT-DECORATION: none">All ASM 
    Journals</A></FONT></TH></TR></TBODY></TABLE></TABLE></BODY></HTML>
